

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION

Pr **SYNJARDY™**

Empagliflozin and metformin hydrochloride tablets

5 mg/500 mg, 5 mg/850 mg, 5 mg/1000 mg, 12.5 mg/500 mg, 12.5 mg/850 mg,
12.5 mg/1000 mg

Combinations of oral blood glucose lowering drugs

ATC Code: A10BD20

Boehringer Ingelheim (Canada) Ltd
5180 South Service Rd
Burlington, ON L7L 5H4

Date of Revision:
September 18, 2017

Submission Control No: 206979
0289-10

TABLE OF CONTENTS

PART I: HEALTH PROFESSIONAL INFORMATION.....	3
SUMMARY PRODUCT INFORMATION	3
INDICATIONS AND CLINICAL USE.....	3
CONTRAINDICATIONS	4
WARNINGS AND PRECAUTIONS.....	5
ADVERSE REACTIONS.....	14
DRUG INTERACTIONS	21
DOSAGE AND ADMINISTRATION	28
OVERDOSAGE	30
ACTION AND CLINICAL PHARMACOLOGY	30
STORAGE AND STABILITY	35
SPECIAL HANDLING INSTRUCTIONS	35
DOSAGE FORMS, COMPOSITION AND PACKAGING	35
PART II: SCIENTIFIC INFORMATION	37
PHARMACEUTICAL INFORMATION.....	37
CLINICAL TRIALS.....	38
DETAILED PHARMACOLOGY	50
TOXICOLOGY	50
REFERENCES	54
PART III: PATIENT MEDICATION INFORMATION	56

Pr SYNJARDY™

Empagliflozin/Metformin Hydrochloride Tablets

PART I: HEALTH PROFESSIONAL INFORMATION

SUMMARY PRODUCT INFORMATION

Route of Administration	Dosage Form / Strength	Clinically Relevant Nonmedicinal Ingredients
Oral	Film coated tablets 5 mg/500 mg, 5 mg/850 mg, 5 mg/1000 mg, 12.5 mg/500 mg, 12.5 mg/850 mg, 12.5 mg/1000 mg.	<i>For a complete listing see DOSAGE FORMS, COMPOSITION and PACKAGING section.</i>

INDICATIONS AND CLINICAL USE

SYNJARDY (empagliflozin and metformin hydrochloride) is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus inadequately controlled on:

- metformin;
- sulfonylurea in combination with metformin;
- pioglitazone in combination with metformin;
- insulin in combination with metformin;

Or in patients already being treated and achieving glycemic control with:

- metformin and empagliflozin as separate tablets (see [CLINICAL TRIALS](#));
- sulfonylurea in combination with metformin and empagliflozin as separate tablets (see [CLINICAL TRIALS](#));
- pioglitazone in combination with metformin and empagliflozin as separate tablets (see [CLINICAL TRIALS](#));
- insulin in combination with metformin and empagliflozin as separate tablets (see [CLINICAL TRIALS](#));

Important Limitations of Use: In combination therapy, use of empagliflozin with insulin mix (regular or analogue mix) has not been studied. Therefore, SYNJARDY should not be used with insulin mix (see [CLINICAL TRIALS](#)).

Pediatrics (< 18 years of age): SYNJARDY should not be used in pediatric patients. Safety and effectiveness of SYNJARDY have not been studied in patients under 18 years of age.

Geriatrics (≥65 years of age): A greater increase in risk of adverse reactions was seen with empagliflozin in the elderly, compared to younger patients, therefore, SYNJARDY should be used with caution in this population (see [WARNINGS AND PRECAUTIONS, Special Populations](#), [DOSAGE AND ADMINISTRATION](#) and [ACTION AND CLINICAL PHARMACOLOGY](#)). Empagliflozin is expected to have diminished efficacy in elderly patients as older patients are more likely to have impaired renal function.

Metformin is eliminated by the kidney and the risk of serious adverse reactions to the drug is greater in patients with impaired renal function. SYNJARDY should only be used in patients with normal renal function (see [CONTRAINDICATIONS](#) and [WARNINGS AND PRECAUTIONS, Renal](#)). Because aging is associated with reduced renal function, SYNJARDY should be used with caution in geriatric patients. SYNJARDY treatment should not be initiated in patients older than 80 years of age, unless measurement of creatinine clearance demonstrates that renal function is not reduced (see [WARNINGS AND PRECAUTIONS](#), Endocrine and Metabolism, Lactic Acidosis, Special Populations, Geriatrics, and [DOSAGE AND ADMINISTRATION](#)).

CONTRAINDICATIONS

- Unstable and/or insulin-dependent (Type I) diabetes mellitus.
- Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma, history of ketoacidosis with or without coma.
- In patients with a history of lactic acidosis, irrespective of precipitating factors.
- In the presence of renal impairment or renal disease [as suggested by serum creatinine levels above the upper limit of normal range, $\geq 136 \mu\text{mol/L}$ (males), $\geq 124 \mu\text{mol/L}$ (females) or abnormal creatinine clearance $< 60 \text{ mL/min}$] which may result from conditions such as cardiovascular collapse (shock), acute myocardial infarction, and septicemia, or when renal function is not known (see [WARNINGS and PRECAUTIONS](#)).
- In excessive alcohol intake, acute or chronic.
- In patients suffering from severe hepatic dysfunction, since severe hepatic dysfunction has been associated with some cases of lactic acidosis; in patients with clinical or laboratory evidence of hepatic disease.
- In cases of cardiovascular collapse and in disease states associated with hypoxemia such as cardiorespiratory insufficiency, which are often associated with hyperlactacidemia.
- During stress conditions, such as severe infections, trauma or surgery and the recovery phase thereafter.
- In patients suffering from dehydration or shock.
- Known hypersensitivity or allergy to empagliflozin, metformin HCl or any of the excipients. For a complete listing (see [DOSAGE FORMS, COMPOSITION AND PACKAGING](#)).
- During pregnancy and breastfeeding.

- Period around administration of iodinated contrast materials, because the use of such products may result in acute alteration of renal function, SYNJARDY should be temporarily discontinued (see [WARNINGS AND PRECAUTIONS, Renal](#)).

WARNINGS AND PRECAUTIONS

Serious Warnings and Precautions

Lactic Acidosis

- Lactic acidosis is a rare, but serious, metabolic complication that occurs due to metformin accumulation during treatment with SYNJARDY (see [Endocrine and Metabolism, Lactic Acidosis](#)).
- Patients should be cautioned against excessive alcohol intake, either acute or chronic, when taking SYNJARDY, since alcohol intake potentiates the effect of metformin on lactate metabolism (see [Endocrine and Metabolism, Lactic Acidosis](#)).

Diabetic Ketoacidosis

- Clinical trial and post-market cases of diabetic ketoacidosis (DKA), a serious life-threatening condition requiring urgent hospitalization, have been reported in patients with type 2 diabetes mellitus (T2DM) treated with SYNJARDY and other sodium-glucose co-transporter 2 (SGLT2) inhibitors. Some cases of DKA have been fatal. A number of these cases have been atypical with blood glucose values below 13.9 mmol/L (250 mg/dL) (see [ADVERSE REACTIONS](#)).
- Patients should be assessed for diabetic ketoacidosis immediately if non-specific symptoms such as difficulty breathing, nausea, vomiting, abdominal pain, confusion, anorexia, excessive thirst and unusual fatigue or sleepiness occur, regardless of blood glucose level, and SYNJARDY should be **discontinued immediately**.
- SYNJARDY should not be used for the treatment of DKA or in patients with a history of DKA.
- SYNJARDY is not indicated, and should not be used, in patients with type 1 diabetes.

General

SYNJARDY is not indicated for use in patients with type 1 diabetes and should not be used for the treatment of diabetic ketoacidosis.

Cardiovascular

Empagliflozin

Use in Patients at Risk for Volume Depletion, Hypotension and/or Electrolyte Imbalances: SYNJARDY is not recommended for use in patients who are volume depleted.

Due to its mechanism of action, SYNJARDY causes diuresis that may be associated with decreases in blood pressure.

Caution should be exercised in patients for whom an empagliflozin induced drop in blood pressure could pose a risk, such as patients with known cardiovascular disease, patients on antihypertensive therapy (particularly loop diuretics), elderly patients, patients with low systolic blood pressure, or in case of intercurrent conditions that may lead to volume depletion (such as gastrointestinal illness).

Careful monitoring of volume status is recommended. Temporary interruption of SYNJARDY should be considered for patients who develop volume depletion until the depletion is corrected (see [WARNINGS AND PRECAUTIONS](#), [Monitoring and Laboratory Tests](#), and [ADVERSE REACTIONS](#))

Metformin hydrochloride

Hypoxic states: Cardiovascular collapse (shock) from whatever cause, acute congestive heart failure, acute myocardial infarction and other conditions characterized by hypoxemia have been associated with lactic acidosis and may also cause prerenal azotemia. When such event occurs in patients on SYNJARDY therapy, the drug should be promptly discontinued.

Endocrine and Metabolism

Empagliflozin

Diabetic ketoacidosis: Clinical trial and post-market cases of diabetic ketoacidosis (DKA), a serious life-threatening condition requiring urgent hospitalization, have been reported in patients treated with empagliflozin and other SGLT2 inhibitors. Some cases of DKA have been fatal. In a number of reported cases, the presentation of the condition was atypical with only moderately increased blood glucose values, below 14 mmol/L (250 mg/dL).

SYNJARDY is not indicated, and should not be used, in patients with type 1 diabetes. The diagnosis of type 2 diabetes mellitus should therefore be confirmed before initiating SYNJARDY.

Diabetic ketoacidosis must be considered in the event of non-specific symptoms such as nausea, vomiting, anorexia, abdominal pain, excessive thirst, difficulty breathing, confusion, unusual fatigue or sleepiness.

If these symptoms occur, regardless of blood glucose level, patients should discontinue SYNJARDY treatment and be assessed for diabetic ketoacidosis immediately.

Interruption of treatment with SYNJARDY should be considered in type 2 diabetes patients who are hospitalized for major surgical procedures, serious infections or acute serious medical illnesses.

SGLT2 inhibitors have been shown to increase blood ketones in clinical trial subjects. Conditions that can precipitate DKA while taking empagliflozin include patients on a very low carbohydrate diet (as the combination may further increase ketone body production), dehydration, high alcohol consumption, and a low beta-cell function reserve. SYNJARDY should be used with caution in these patients. These patients should be monitored closely.

Caution should be taken when reducing the insulin dose in patients requiring insulin (see [DOSAGE AND ADMINISTRATION](#)).

Use with medications known to cause hypoglycemia:

Empagliflozin

Insulin secretagogues and insulin are known to cause hypoglycemia. The use of SYNJARDY in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin was associated with a higher rate of hypoglycemia compared with placebo in a clinical trial (see [ADVERSE REACTIONS](#)). Therefore, a lower dose of the insulin secretagogue or insulin may be required to reduce the risk of hypoglycemia when used in combination with SYNJARDY (see [DOSAGE AND ADMINISTRATION](#)).

Increases in low-density lipoprotein (LDL-C): Dose-related increases in LDL-C are seen with empagliflozin treatment (see [ADVERSE REACTIONS](#)). LDL-C levels should be monitored.

Metformin hydrochloride

Hypoglycemia: Hypoglycemia does not occur in patients receiving metformin alone under usual circumstances of use, but could occur when caloric intake is deficient, when strenuous exercise is not compensated by caloric supplementation or during concomitant use with other glucose lowering agents or ethanol.

Elderly, debilitated or malnourished patients and those with adrenal or pituitary insufficiency or alcohol intoxication are particularly susceptible to hypoglycemic effects.

Hypoglycemia may be difficult to recognize in the elderly, and in people who are taking beta-adrenergic blocking drugs.

The patient should be warned about driving a vehicle or operating machinery under these conditions where risk of hypoglycaemia is present.

Lactic Acidosis: Lactic acidosis is a rare, but serious, metabolic complication that can occur due to metformin accumulation during treatment with SYNJARDY; when it occurs, it is fatal in approximately 50% of cases. Lactic acidosis may also occur in association with a number of pathophysiologic conditions, including diabetes mellitus, and whenever there is significant tissue hypoperfusion and hypoxemia. Lactic acidosis is characterized by elevated blood lactate levels

(>5 mmol/L), decreased blood pH, electrolyte disturbances with an increased anion gap, and an increased lactate/pyruvate ratio. When metformin is implicated as the cause of lactic acidosis, metformin plasma levels >5 µg/mL are generally found.

The reported incidence of lactic acidosis in patients receiving metformin hydrochloride is very low (approximately 0.03 cases/1000 patient-years, with approximately 0.015 fatal cases/1000 patient-years). Reported cases have occurred primarily in diabetic patients with significant renal insufficiency, including both intrinsic renal disease and renal hypoperfusion, often in the setting of multiple concomitant medical/surgical problems and multiple concomitant medications.

Patients with congestive heart failure requiring pharmacologic management, in particular those with unstable or acute congestive heart failure who are at risk of hypoperfusion and hypoxemia, are at increased risk of lactic acidosis. In particular, treatment of the elderly should be accompanied by careful monitoring of renal function. SYNJARDY treatment should not be initiated in patients ≥80 years of age unless measurement of creatinine clearance demonstrates that renal function is not reduced, as these patients are more susceptible to developing lactic acidosis. The risk of lactic acidosis increases with the degree of renal dysfunction and the patient's age. The risk of lactic acidosis may, therefore, be significantly decreased by regular monitoring of renal function in patients taking metformin and by use of the minimum effective dose of metformin.

In addition, SYNJARDY should be promptly withheld in the presence of any condition associated with hypoxemia, dehydration, or sepsis. Because impaired hepatic function may significantly limit the ability to clear lactate, SYNJARDY should generally be avoided in patients with clinical or laboratory evidence of hepatic disease.

Patients should be cautioned against excessive alcohol intake, either acute or chronic, when taking SYNJARDY since alcohol potentiates the effects of metformin hydrochloride on lactate metabolism. In addition, SYNJARDY should be temporarily discontinued prior to any intravascular radiocontrast study and for any surgical procedure.

The onset of lactic acidosis often is subtle, and accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, increasing somnolence, and nonspecific abdominal distress. There may be associated hypothermia, hypotension, and resistant bradyarrhythmias with more marked acidosis. The patient and the patient's physician must be aware of the possible importance of such symptoms and the patient should be instructed to notify the physician immediately if they occur. SYNJARDY should be withdrawn until the situation is clarified. Serum electrolytes, ketones, blood glucose, and if indicated, blood pH, lactate levels, and even blood metformin levels may be useful. Once a patient is stabilized on any dose level of metformin, gastrointestinal symptoms, which are common during initiation of therapy, are unlikely to be drug related. Later occurrence of gastrointestinal symptoms could be due to lactic acidosis or other serious disease.

Levels of fasting venous plasma lactate above the upper limit of normal but less than 5 mmol/L in patients taking metformin do not necessarily indicate impending lactic acidosis and may be explainable by other mechanisms, such as poorly controlled diabetes or obesity, vigorous physical activity, or technical problems in sample handling.

Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).

Lactic acidosis is a medical emergency that must be treated in a hospital setting. In a patient with lactic acidosis who is taking SYNJARDY, the drug should be discontinued immediately and general supportive measures promptly instituted. Because metformin hydrochloride is dialyzable (with a clearance of up to 170 mL/min under good hemodynamic conditions), prompt hemodialysis is recommended to correct the acidosis and remove the accumulated metformin. (see [CONTRAINDICATIONS](#) and [WARNINGS AND PRECAUTIONS, Cardiovascular, Hepatic and Renal](#)).

Physicians should instruct their patients to recognize the symptoms which could be a signal of the onset of lactic acidosis. If acidosis of any kind develops, SYNJARDY™ should be discontinued immediately.

Change in clinical status of previously controlled diabetes patients: A diabetic patient previously well controlled on SYNJARDY who develops laboratory abnormalities or clinical illness (especially vague and poorly defined illness) should be evaluated promptly for evidence of ketoacidosis or lactic acidosis. Evaluation should include serum electrolytes and ketones, blood glucose and, if indicated, blood pH, lactate, pyruvate and metformin levels. If acidosis of either form occurs, SYNJARDY must be stopped immediately and appropriate corrective measures initiated.

Loss of control of blood glucose: When a patient stabilized on any diabetic regimen is exposed to stress such as fever, trauma, infection, or surgery, a temporary loss of glycemic control may occur. At such times, it may be necessary to withhold SYNJARDY and temporarily administer insulin. SYNJARDY may be reinstated after the acute episode is resolved.

Vitamin B₁₂ levels: Impairment of vitamin B₁₂ absorption has been reported in some patients treated with metformin. Therefore, measurements of serum vitamin B₁₂ are advisable at least every one to two years in patients on long-term treatment with SYNJARDY. A decrease to subnormal levels of previously normal serum Vitamin B₁₂ levels, without clinical manifestations, is observed in approximately 7% of patients receiving metformin in controlled clinical trials of 29 weeks duration. Such decrease, possibly due to interference with B₁₂ absorption from the B₁₂-intrinsic factor complex, is, however, very rarely associated with anemia and appears to be rapidly reversible with discontinuation of metformin or with Vitamin B₁₂ supplementation. Measurement of hematologic parameters on an annual basis is advised in patients on SYNJARDY and any apparent abnormalities should be appropriately investigated and managed (see [WARNINGS AND PRECAUTIONS, Monitoring and Laboratory Tests](#)). Certain individuals (those with inadequate Vitamin B₁₂ or calcium intake or absorption) appear to be predisposed to developing subnormal Vitamin B₁₂ levels.

Genitourinary *Empagliflozin*

Genital Mycotic Infections: SYNJARDY increases the risk of genital mycotic infections, particularly for patients with a history of genital mycotic infections (see [ADVERSE REACTIONS](#)).

Urinary tract infections (including urosepsis and pyelonephritis): SYNJARDY increases the risk for urinary tract infections (see [ADVERSE REACTIONS](#)). There have been postmarketing reports of serious urinary tract infections including urosepsis and pyelonephritis, some of them requiring hospitalization, in patients receiving empagliflozin and other SGLT2 inhibitors. Evaluate patients for signs and symptoms of urinary tract infections and treat promptly, if indicated.

Hematologic

Empagliflozin

Elevated Hemoglobin and Hematocrit: Mean hemoglobin and hematocrit increased in patients administered SYNJARDY, as did the frequency of patients with abnormally elevated values for hemoglobin/hematocrit (see [ADVERSE REACTIONS](#)). SYNJARDY should be used with caution in patients with an elevated hematocrit.

Hepatic/Biliary/Pancreatic

SYNJARDY is contraindicated in patients with clinical or laboratory evidence of hepatic disease (see [CONTRAINDICATIONS](#)).

Empagliflozin

Substantial elevations in hepatic transaminases have been reported in empagliflozin treated patients in clinical trials; however a causal relationship with empagliflozin has not been established (see [DOSAGE AND ADMINISTRATION](#) and [ACTION AND CLINICAL PHARMACOLOGY](#)).

Metformin hydrochloride

Impaired hepatic function has been associated with some cases of lactic acidosis.

Immune

Hypersensitivity Reactions: SYNJARDY is contraindicated in patients with a history of hypersensitivity reaction to the active substance or to any of the excipients (see [CONTRAINDICATIONS](#)). Serious hypersensitivity reactions, including rash, angioedema and urticaria, have been observed with empagliflozin in post marketing reports (see [ADVERSE REACTIONS](#)).

Peri-Operative Considerations

Metformin hydrochloride

SYNJARDY therapy should be temporarily suspended for any surgical procedure (except minor procedures not associated with restricted intake of food and fluids). SYNJARDY should be discontinued 2 days before surgical intervention and should not be restarted until the patient's oral intake has resumed and renal function has been evaluated as normal.

Renal

SYNJARDY is contraindicated in patients with a serum creatinine level above the upper limit of normal range [serum creatinine levels ≥ 136 $\mu\text{mol/L}$ (males) or ≥ 124 $\mu\text{mol/L}$ females)], abnormal creatinine clearance (<60 mL/min), or when renal function is not known (see [CONTRAINDICATIONS](#)). Renal function should be assessed prior to initiation of SYNJARDY and regularly thereafter (see [DOSAGE AND ADMINISTRATION](#)).

Empagliflozin

Empagliflozin increases serum creatinine and decreases eGFR in a dose dependent fashion. Renal function abnormalities can occur after initiating empagliflozin. Patients with hypovolemia are more susceptible to these changes (see [ADVERSE REACTIONS](#)).

Metformin hydrochloride

Metformin is known to be substantially excreted by the kidney and the risk of metformin accumulation and lactic acidosis increases with the degree of impairment of renal function. Thus, patients with serum creatinine levels above the upper limit of the normal range for their age should not receive SYNJARDY.

Before initiation of SYNJARDY therapy and every 6 months while on SYNJARDY therapy, renal function should be assessed and verified as being within normal range.

In patients in whom development of renal dysfunction is anticipated, renal function should be assessed more frequently and SYNJARDY discontinued if evidence of renal impairment is present.

Special caution should be exercised in situations where renal function may become impaired, for example when initiating antihypertensive therapy or diuretic therapy and when starting therapy with an NSAID.

Use of concomitant medications that may affect renal function or metformin disposition:

Concomitant medication(s) that may affect renal function or result in significant hemodynamic change or may interfere with disposition of SYNJARDY, such as cationic drugs that are eliminated by renal tubular secretion should be used with caution (see [DRUG INTERACTIONS](#)).

Radiological studies involving the use of intravascular iodinated contrast materials - for example, intravenous urogram, intravenous cholangiography, angiography, and computed tomography (CT) scans with intravascular contrast material:

Intravascular contrast studies with iodinated materials can lead to acute alteration of renal function and have been associated with lactic acidosis in patients receiving metformin (see [CONTRAINDICATIONS](#)). Therefore, in patients in whom any such study is planned, SYNJARDY should be temporarily discontinued at the time of or prior to the procedure, and withheld for 48 hours subsequent to the procedure and reinstated only after renal function has been re-evaluated and found to be normal.

Special Populations

Pregnant Women: SYNJARDY is contraindicated during pregnancy (see [CONTRAINDICATIONS](#)). Safety in pregnant women has not been established. When pregnancy is detected, SYNJARDY should be discontinued.

Empagliflozin

There are limited data from the use of empagliflozin in pregnant women. Based on results from animal studies, SGLT-2 inhibitors may affect renal development and maturation (see [TOXICOLOGY](#)).

Metformin hydrochloride

There are no adequate and well-controlled studies of metformin in pregnant women.

Metformin was not teratogenic in rats and rabbits at doses up to 600 mg/kg/day, or about two times the maximum recommended human daily dose on a body surface area basis. Determination of fetal concentrations demonstrated a partial placental barrier to metformin. Because animal reproduction studies are not always predictive of human response, the use of SYNJARDY is contraindicated during pregnancy (see [CONTRAINDICATIONS](#)).

Nursing Women: SYNJARDY is contraindicated in nursing women (see [CONTRAINDICATIONS](#)).

Empagliflozin

No data in humans are available on excretion of empagliflozin into milk. Available animal data have shown excretion of empagliflozin in milk reaching levels up to 5 times higher than that in the maternal plasma (see [TOXICOLOGY](#)). As functional maturation of the kidneys in humans continues in the first 2 years of life, there may be a risk to the developing kidney if SYNJARDY is used during breastfeeding.

Metformin hydrochloride

Studies in lactating rats show that metformin is excreted into milk and reaches levels comparable to those in plasma. Metformin hydrochloride is also excreted into human breast milk.

Pediatrics (< 18 years of age): Safety and effectiveness of SYNJARDY have not been studied in pediatric patients. Therefore SYNJARDY should not be used in this patient population.

Geriatrics (≥65 years of age):

Empagliflozin

A total of 2721 (32%) patients treated with empagliflozin were 65 years and over, and 491 (6%) were 75 years and over in the pool of double-blind, controlled clinical safety and efficacy studies of empagliflozin.

A greater increase in risk of adverse reactions related to urinary tract infections was seen with empagliflozin in the elderly, compared to younger patients and increased in patients who were 75 years of age and older. A greater increase in risk of adverse reactions related to volume depletion was seen with empagliflozin in patients ≥ 75 years of age. SYNJARDY is expected to have diminished efficacy in elderly patients as older patients are more likely to have impaired renal function. Therefore, SYNJARDY should be used with caution in this population (see [INDICATIONS AND CLINICAL USE](#), [DOSAGE AND ADMINISTRATION](#) and [ACTION AND CLINICAL PHARMACOLOGY](#)). Therapeutic experience in patients aged ≥ 85 years is limited. Initiation of SYNJARDY therapy in this population is not recommended.

Metformin hydrochloride

Controlled clinical studies of metformin HCl did not include sufficient numbers of elderly patients to determine whether they respond differently from younger patients, although other reported clinical experience has not identified differences in responses between the elderly and younger patients. Metformin is known to be substantially excreted by the kidney and because the risk of serious adverse reactions to the drug is greater in patients with impaired renal function, it should only be used in patients with normal renal function (see [CONTRAINDICATIONS](#) and [WARNINGS and PRECAUTIONS](#)). Because aging is associated with reduced renal function, SYNJARDY should be used with caution as age increases with careful and regular monitoring of renal function.

Monitoring and Laboratory Tests

Periodic cardiovascular, ophthalmic, hematological, hepatic, and renal assessments are recommended (See [WARNINGS AND PRECAUTIONS](#)).

Blood Glucose and HbA1c: Response to SYNJARDY treatment should be monitored by periodic measurements of fasting blood glucose and HbA1c levels with a goal of decreasing these levels toward the normal range.

Due to its mechanism of action, patients taking SYNJARDY will test positive for glucose in their urine.

Hematology: Initial and periodic monitoring of hematologic parameters (e.g., hemoglobin/hematocrit and red blood cell indices) should be performed regularly. While megaloblastic anemia has rarely been seen with metformin therapy, if this is suspected, Vitamin B₁₂ deficiency should be excluded.

Renal Function: SYNJARDY is contraindicated in patients with renal impairment (see [CONTRAINDICATIONS](#) and [DOSAGE AND ADMINISTRATION](#)). Renal function should be assessed prior to initiation of SYNJARDY and regularly thereafter with more frequent monitoring in patients whose eGFR decreases.

Monitoring of renal function is recommended prior to and following initiation of any concomitant drug which might have an impact on renal function.

Reduced Intravascular Volume: SYNJARDY is not recommended for use in patients who are volume depleted (see [DOSAGE AND ADMINISTRATION](#)). Before initiating SYNJARDY,

assess volume status, particularly in patients at risk (see [WARNINGS AND PRECAUTIONS, Cardiovascular](#), and [DOSAGE AND ADMINISTRATION](#)), as well as in case of intercurrent conditions that may lead to fluid loss (such as a gastrointestinal illness) for patients already taking SYNJARDY. In these patients, careful monitoring of volume status (e.g., physical examination, blood pressure measurements, laboratory tests, including hematocrit, serum electrolytes and renal function tests) is recommended. Temporary interruption of treatment with SYNJARDY should be considered until fluid loss is corrected.

LDL-Cholesterol: LDL-cholesterol levels should be measured at baseline and at regular intervals during treatment with SYNJARDY due to dose-dependent increases in LDL-C seen with empagliflozin therapy.

ADVERSE REACTIONS

There have been no clinical studies conducted with SYNJARDY (empagliflozin/metformin hydrochloride) tablets.

Adverse Drug Reaction Overview

Empagliflozin

A total of 10 004 patients with type 2 diabetes were treated with empagliflozin in clinical studies to evaluate the safety of empagliflozin, alone or in combination to support the indications. In clinical trials 2856 patients received treatment with empagliflozin 10 mg and 3738 patients received treatment with empagliflozin 25 mg for at least 24 weeks; 601 were treated with empagliflozin 10 mg and 881 patients were treated with empagliflozin 25 mg for at least 76 weeks.

In these trials, the frequency of AEs leading to discontinuation was similar by treatment groups for placebo (5.3%) and empagliflozin 10 mg (4.8%) and 25 mg (4.9%).

Placebo controlled double-blinded trials of 18 to 24 weeks of exposure included 2971 patients, of which 995 were treated with placebo, 999 were treated with empagliflozin 10 mg and 977 were treated with empagliflozin 25 mg.

The most frequent adverse drug reaction was hypoglycaemia, which depended on the type of background therapy used in the respective studies (see [ADVERSE REACTIONS, Hypoglycemia](#)).

Metformin hydrochloride

Lactic Acidosis: very rare (<1/10, 000 and isolated reports) (see [WARNINGS AND PRECAUTIONS](#), and [OVERDOSAGE](#)).

Gastrointestinal Reactions: very common: (>1/10) Gastrointestinal symptoms (diarrhea, nausea, vomiting, abdominal bloating, flatulence, and anorexia) are the most common reactions to metformin HCl and are approximately 30% more frequent in patients on metformin monotherapy than in placebo-treated patients, particularly during initiation of metformin therapy.

Because significant diarrhea and/or vomiting can cause dehydration and prerenal azotemia, SYNJARDY should be temporarily discontinued, under such circumstances.

For patients who have been stabilized on metformin, nonspecific gastrointestinal symptoms should not be attributed to therapy unless intercurrent illness or lactic acidosis have been excluded.

Special Senses: common ($\geq 1/100$): During initiation of metformin HCl therapy complaints of taste disturbance are common, i.e. metallic taste.

Dermatologic Reactions: very rare ($< 1/10,000$ and isolated reports): The incidence of rash/dermatitis in controlled clinical trials was comparable to placebo for metformin monotherapy and to sulfonylurea for metformin/sulfonylurea therapy. Reports of skin reactions such as erythema, pruritus, and urticaria are very rare.

Hematologic: Decrease of vitamin B₁₂ absorption with decrease of serum levels during long-term use of metformin is rare ($\geq 1/10,000$ and $< 1/1,000$). Consideration of such etiology is recommended if a patient presents with megaloblastic anemia.

Hepatic: very rare ($< 1/10,000$ and isolated reports): Liver function tests abnormalities or hepatitis resolving upon metformin discontinuation has been documented in isolated reports.

Empagliflozin and Metformin hydrochloride

A total of 7,052 patients with type 2 diabetes were treated in clinical studies to evaluate the safety of empagliflozin plus metformin, of which 4,740 patients were treated with empagliflozin plus metformin, either alone, or in combination to support the indications. In these trials 1,270 patients received treatment with empagliflozin 10 mg plus metformin and 2,065 patients treatment with empagliflozin 25 mg plus metformin for at least 24 weeks and 643 or 1,286 patients for at least 76 weeks.

Placebo controlled double-blinded trials of 18 to 24 weeks of exposure included 3456 patients, of which 1271 were treated with empagliflozin 10 mg plus metformin and 1259 with empagliflozin 25 mg plus metformin.

The most frequently reported adverse event in clinical trials was hypoglycaemia, which depended on the type of background therapy used in the respective studies (see description of selected side effects).

No additional side effects were identified in clinical trials with empagliflozin plus metformin compared to the side effects of the single components.

Clinical Trial Adverse Drug Reactions

Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.

In a pooled dataset of the five 24-week placebo-controlled clinical trials and 18-week data from the placebo-controlled study as add-on to insulin therapy, adverse events regardless of causality that occurred in $\geq 1\%$ of patients receiving empagliflozin and more commonly than in patients given placebo (excluding hypoglycemia), are shown in [Table 1](#).

Table 1 Adverse Events Reported in $\geq 1\%$ of Patients Treated with Empagliflozin and More Frequently than in Patients Treated with Placebo

System organ class Preferred term	Empagliflozin 10 mg n = 999 N (%)	Empagliflozin 25 mg n = 977 N (%)	Placebo n = 995 N (%)
Gastrointestinal disorders			
Nausea	23 (2.3)	11 (1.1)	14 (1.4)
Constipation	14 (1.4)	8 (0.8)	12 (1.2)
Toothache	10 (1.0)	3 (0.3)	5 (0.5)
Dry mouth	3 (0.3)	10 (1.0)	1 (0.1)
General disorders and administration site conditions			
Fatigue	19 (1.9)	6 (0.6)	11 (1.1)
Thirst	15 (1.5)	12 (1.2)	0 (0)
Infections and infestations			
Urinary tract infection	82 (8.2)	60 (6.1)	58 (5.8)
Upper respiratory tract infection	31 (3.1)	39 (4.0)	38 (3.8)
Vaginal infection ¹	6 (1.4)	4 (1.0)	2 (0.4)
Bronchitis	13 (1.3)	9 (0.9)	10 (1.0)
Gastroenteritis	13 (1.3)	10 (1.0)	9 (0.9)
Sinusitis	11 (1.1)	9 (0.9)	7 (0.7)
Vulvovaginal candidiasis ¹	5 (1.1)	3 (0.7)	0 (0)
Vulvovaginal mycotic infection ¹	4 (0.9)	7 (1.7)	0 (0)
Influenza	9 (0.9)	12 (1.2)	11 (1.1)
Vulvitis ¹	0 (0)	5 (1.2)	0 (0)
Investigations			
Weight decreased	5 (0.5)	14 (1.4)	2 (0.2)
Metabolism and nutrition disorders			
Hypoglycemia	78 (7.8)	79 (8.1)	61 (6.1)
Dyslipidemia	39 (3.9)	28 (2.9)	34 (3.4)
Hyperlipidemia	8 (0.8)	12 (1.2)	8 (0.8)
Musculoskeletal and connective tissue disorders			
Arthralgia	24 (2.4)	22 (2.3)	22 (2.2)
Muscle spasms	9 (0.9)	10 (1.0)	7 (0.7)
Renal and urinary disorders			
Pollakiuria	19 (1.9)	15 (1.5)	5 (0.5)
Polyuria	14 (1.4)	10 (1.0)	1 (0.1)
Reproductive system and breast disorders			
Balanoposthitis ²	7 (1.3)	1 (0.2)	0 (0)

System organ class Preferred term	Empagliflozin 10 mg n = 999 N (%)	Empagliflozin 25 mg n = 977 N (%)	Placebo n = 995 N (%)
Vulvovaginal pruritus ¹	11 (2.5)	8 (1.9)	3 (0.6)
Respiratory, thoracic and mediastinal disorders			
Cough	14 (1.4)	12 (1.2)	11 (1.1)

¹Percentages calculated with the number of female subjects in each group as denominator: placebo (N=481), empagliflozin 10 mg (N=443), empagliflozin 25 mg (N=420).

²Percentages calculated with the number of male subjects in each group as denominator: placebo (N=514), empagliflozin 10 mg (N=556), empagliflozin 25 mg (N=557).

Less Common Clinical Trial Adverse Drug Reactions (<1%)

Empagliflozin

Infections and infestations: Balanitis, balanitis candida, candiduria, genital candidiasis, genital infection, genital infection fungal, genitourinary tract infection, penile infection, pyelonephritis, scrotal abscess, urinary tract infection bacterial, urogenital infection fungal, urosepsis, vaginitis bacterial, vulvovaginitis.

Investigations: Blood glucose decreased, blood creatinine increased, glomerular filtration rate decreased, hematocrit increased.

Metabolism and nutrition disorders: Dehydration, hypovolemia.

Renal and urinary disorders: Nocturia, oliguria, renal impairment, renal failure acute, dysuria.

Skin and subcutaneous disorders: Pruritus.

Vascular disorders: Hypotension, orthostatic hypotension.

^aAdverse drug reactions (ADRs) were identified based on a comprehensive assessment of biological plausibility, mechanism of action, dose dependence in incidence rate, time of onset, seriousness and consistency of findings across pivotal Phase 3 clinical studies.

Description of Selected Adverse Reactions

Hypoglycemia: The frequency of hypoglycemia depended on the type of background therapy used in each study (see [Table 2](#)). The incidence of hypoglycaemia is increased when SYNJARDY was administered with insulin or a sulfonylurea (see [WARNINGS AND PRECAUTIONS](#)).

Table 2 Incidence of Overall^a and Severe^b Hypoglycaemic Events in Controlled Clinical Studies

Background with Metformin (24 weeks)			
	Placebo+ Metformin (n=206)	EMPAGLIFLOZIN 10 mg + Metformin (n=217)	EMPAGLIFLOZIN 25 mg + Metformin (n=214)
Overall (%)	0.5	1.8	1.4
Severe (%)	0	0	0
Background with Metformin + Sulfonylurea (24 weeks)			
	Placebo (n=225)	EMPAGLIFLOZIN 10 mg +Metformin+ Sulfonylurea (n=224)	EMPAGLIFLOZIN 25 mg + Metformin + Sulfonylurea (n=217)
Overall (%)	8.4	16.1	11.5
Severe (%)	0	0	0
Background with Pioglitazone +/- Metformin (24 weeks)			
	Placebo (n=165)	EMPAGLIFLOZIN 10 mg +Pioglitazone+/- Metformin (n=165)	EMPAGLIFLOZIN 25 mg + Pioglitazone +/- Metformin (n=168)
Overall (%)	1.8	1.2	2.4
Severe (%)	0	0	0
In combination with MDI Insulin + Metformin (18 weeks)			
	Placebo (n=135)	EMPAGLIFLOZIN 10 mg (n=128)	EMPAGLIFLOZIN 25 mg (n=137)
Overall (%)	40	39.1	41.6
Severe (%)	0.7	0	0.7

^aOverall hypoglycaemic events: plasma or capillary glucose of less than or equal to 3.89 mmol/L

^bSevere hypoglycaemic events: requiring assistance regardless of blood glucose

Twice Daily Dosing

The incidence of hypoglycemia in a Phase 2 clinical study with twice daily dosing (empagliflozin in combination with metformin) was reported in four patients, with one patient in treatment arm empagliflozin 10 mg once daily (0.5%), empagliflozin 5 mg twice daily (0.5%), empagliflozin 25 mg once daily (0.5%) and placebo (0.9%) respectively; none in the empagliflozin 12.5 mg twice daily arm. There were no cases of severe hypoglycemia reported in the empagliflozin or placebo groups.

Urinary tract infection: In a pooled dataset of the five 24-week placebo-controlled clinical trials and 18-week data from the placebo-controlled study as add-on to insulin therapy, the frequency of urinary tract infections (e.g., urinary tract infection, asymptomatic bacteriuria, and cystitis) occurred in 9.3%, 7.6%, and 7.6% of patients treated with empagliflozin 10 mg, 25 mg, and placebo, respectively. Patients with a history of chronic or recurrent urinary tract infections were more likely to experience a urinary tract infection.

Urinary tract infection events were reported more frequently in female patients (18.3% and 15.5% for empagliflozin 10 mg and 25 mg respectively, 12.5% for placebo) than in male patients (2.2% and 1.6% for empagliflozin 10 mg and 25 mg respectively, 3.1% for placebo). The

incidence of pyelonephritis and urosepsis with empagliflozin was <0.1% and similar to placebo.

In elderly patients the incidence of urinary tract infections with empagliflozin compared to placebo was greater than in younger patients (see [WARNINGS AND PRECAUTIONS](#)).

Genital Mycotic Infections: In a pooled dataset of the five 24-week placebo-controlled clinical trials and 18-week data from the placebo-controlled study as add-on to insulin therapy, the frequency of vaginal moniliasis, vulvovaginitis, balanitis and other genital infections were reported more frequently for empagliflozin 10 mg (4.1%) and empagliflozin 25 mg (3.7%) compared to placebo (0.9%). Patients with a prior history of genital infections were more likely to experience a genital infection event.

Genital infection events were reported more frequently in female patients (5.4%, 6.4% and 1.5%, for empagliflozin 10 mg, 25 mg, or placebo, respectively) than in male patients (3.1%, 1.6% and 0.4%, for empagliflozin 10 mg, 25 mg, or placebo, respectively). Discontinuation from study due to genital infection occurred in 0.2% of patients treated with either empagliflozin 10 or 25 mg and 0% of placebo treated patients.

Phimosis occurred more frequently in patients treated with empagliflozin 10 mg (less than 0.1%) and empagliflozin 25 mg (0.1%) than placebo (0%) in the pooled 24-week placebo-controlled trials.

Increased urination: In the pool of five placebo-controlled clinical trials, adverse reactions of increased urination (e.g., polyuria, pollakiuria, and nocturia) were reported by 3.4%, 3.2% and 1.0% of patients treated with empagliflozin 10 mg, 25 mg and placebo, respectively. Nocturia was reported by 0.3%, 0.8%, and 0.4% of patients treated with empagliflozin 10 mg, 25 mg, and placebo respectively.

Volume depletion: Adverse reactions related to volume depletion (including the predefined terms blood pressure (ambulatory) decreased, blood pressure systolic decreased, dehydration, hypotension, hypovolemia, orthostatic hypotension, and syncope) were reported for 0.5%, 0.3%, and 0.3% of patients treated with empagliflozin 10 mg, 25 mg and placebo, respectively. The incidence of volume depletion was increased in patients ≥ 75 years of age, with adverse events reported for 2.3%, 4.4%, and 2.1% of patients treated with empagliflozin 10 mg, 25 mg, and placebo, respectively.

Cardiovascular safety: In a prospective meta-analysis of independently adjudicated cardiovascular events from 7 phase II and III clinical studies involving 8247 patients with type 2 diabetes (placebo N=2816, empagliflozin 10 mg N=2614, and empagliflozin 25 mg N=2817), empagliflozin did not increase cardiovascular risk as measured by a composite endpoint based on time to first occurrence of CV death (including fatal stroke and fatal myocardial infarction), non-fatal myocardial infarction, non-fatal stroke, or hospitalization for unstable angina.

Blood creatinine increased and glomerular filtration rate decreased: In placebo-controlled, double-blind studies up to 76 weeks, increases in creatinine (mean change from baseline after 12 weeks: empagliflozin 10 mg 0.02 mg/dL, empagliflozin 25 mg 0.01 mg/dL) and decreases in

estimated glomerular filtration rates (mean change from baseline after 12 weeks: empagliflozin 10 mg $-1.34 \text{ mL/min/1.73m}^2$, empagliflozin 25 mg $-1.37 \text{ mL/min/1.73m}^2$) have been observed. These changes were reversible in some patients during continuous treatment or after drug discontinuation (see [WARNINGS AND PRECAUTIONS](#), Renal. See [Monitoring and Laboratory Tests](#), Renal Function).

Diabetic ketoacidosis: Cases of diabetic ketoacidosis (DKA), a serious life-threatening condition requiring urgent hospitalization, have been reported in patients treated with empagliflozin, and other SGLT2 inhibitors. Some cases of DKA have been fatal. (see [WARNINGS AND PRECAUTIONS](#)). SYNJARDY is not indicated, and should not be used, in patients with type 1 diabetes. In some cases, the presentation of the condition was atypical, with blood glucose values only moderately elevated (below 14 mmol/L (250 mg/dL). (see [WARNINGS AND PRECAUTIONS](#)).

Abnormal Hematologic and Clinical Chemistry Findings

Empagliflozin

Increases in serum creatinine and decreases in eGFR: In a pool of four-placebo-controlled trials, the mean change from baseline for eGFR (mL/min/1.73 m^2) at week 24 was -0.55 , -1.41 and -0.32 , for empagliflozin 10 mg, 25 mg and placebo respectively. The mean change from baseline for creatinine ($\mu\text{mol/L}$) was 0.66 , 1.28 and 0.35 for empagliflozin 10 mg, 25 mg and placebo, respectively.

Increases in serum phosphate: Elevations of serum phosphate above the normal range occurred more frequently in patients receiving empagliflozin than in those receiving placebo (1.5%, 1.9% and 0.4% for empagliflozin 10 mg, 25 mg, and placebo, respectively) in a pool of four placebo-controlled trials.

Low density lipoprotein Cholesterol (LDL-C): In a pool of four placebo-controlled studies, LDL-C increases with empagliflozin were observed. Placebo-corrected mean changes from baseline in LDL-C were 2.3 mg/dL (3.5%) for empagliflozin 10 mg and 3.3 mg/dL (4.6%) for empagliflozin 25 mg.

Hematocrit: In a pool of four placebo-controlled studies, hematocrit increases with empagliflozin were observed. Mean changes from baseline in hematocrit were 2.3%, 2.6% and -0.8% for empagliflozin 10 mg, 25 mg and placebo respectively. Elevations of hematocrit or hemoglobin above the normal ranges occurred more frequently in patients receiving empagliflozin than in those receiving placebo (2.5%, 3.2% and 0.5% for empagliflozin 10 mg, 25 mg, and placebo, respectively).

Metformin hydrochloride

In controlled clinical trials of metformin of 29 weeks duration, a decrease to subnormal levels of previously normal serum Vitamin B₁₂ levels, without clinical manifestations, was observed in approximately 7% of patients. Such decrease, possibly due to interference with B₁₂ absorption from the B₁₂-intrinsic factor complex, is, however, very rarely associated with anemia and appears to be rapidly reversible with discontinuation of metformin or Vitamin B₁₂ supplementation (see [WARNINGS AND PRECAUTIONS](#)).

Post-Market Adverse Drug Reactions

Because these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Empagliflozin

Metabolism and nutrition disorders: diabetic ketoacidosis.

Skin and subcutaneous tissue disorders: allergic skin reactions (e.g. rash, angioedema and urticaria).

Metformin hydrochloride

Gastrointestinal Disorders: Abdominal discomfort, abdominal distension, abdominal pain, abdominal pain upper, constipation, diarrhea, dry mouth, dyspepsia, flatulence, gastric disorder, gastric ulcer, gastrointestinal disorder, nausea, vomiting.

Hepatobiliary Disorders: Liver function tests abnormalities or hepatitis resolving upon metformin discontinuation, autoimmune hepatitis, drug-induced liver injury, hepatitis.

Investigations: Blood lactic acid increased.

Metabolism and Nutrition Disorders: Lactic acidosis, decrease of Vitamin B₁₂ absorption with decrease of serum levels during long-term use of metformin, weight decreased, decreased appetite.

Skin and Subcutaneous Tissue Disorders: Erythema, pruritus, rash, skin lesion, urticarial.

DRUG INTERACTIONS

Overview

Specific pharmacokinetic drug interaction studies with SYNJARDY have not been performed; however, such studies have been conducted with the individual empagliflozin and metformin components.

Empagliflozin

In vitro assessment of interactions

In vitro data suggest that the primary route of metabolism of empagliflozin in humans is glucuronidation by the uridine 5'-diphospho-glucuronosyltransferases UGT2B7, UGT1A3, UGT1A8, and UGT1A9. The relative contribution of each isoform to empagliflozin clearance has not been determined.

Empagliflozin does not inhibit, inactivate, or induce CYP450 isoforms. Empagliflozin does not inhibit UGT1A1. Therefore, no effect of empagliflozin is anticipated on concomitantly administered drugs that are substrates of the major CYP450 isoforms or UGT1A1. The effect of UGT induction on empagliflozin exposure has not been evaluated.

Empagliflozin is a substrate for P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), but it does not inhibit these efflux transporters at therapeutic doses. Based on *in vitro* studies, empagliflozin is considered unlikely to cause interactions with drugs that are P-gp

substrates. Empagliflozin is a substrate of the human uptake transporters OAT3, OATP1B1, and OATP1B3, but not OAT1 and OCT2. Empagliflozin does not inhibit any of these human uptake transporters at clinically relevant plasma concentrations therefore, no effect of empagliflozin is anticipated on concomitantly administered drugs that are substrates of these uptake transporters.

Metformin hydrochloride

In healthy volunteers, the pharmacokinetics of propranolol and ibuprofen were not affected by metformin when coadministered in single-dose interaction studies.

Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid, as compared to sulfonylureas, which are extensively bound to serum proteins.

Drug-Drug Interactions

Empagliflozin

Pharmacokinetic interactions

Effects of other co-administered drugs on empagliflozin

In clinical studies, empagliflozin pharmacokinetics were similar with and without co-administration of metformin, glimepiride, pioglitazone, sitagliptin, linagliptin, warfarin (CYP2C9 substrate), verapamil (P-gp inhibitor), ramipril, simvastatin (CYP3A4, OATP1B1, OATP1B3 substrate), torasemide and hydrochlorothiazide in healthy volunteers (see [Table 3](#)). Empagliflozin overall exposure (AUC) increased by 59%, 35% and 53%, when co-administered with gemfibrozil (CYP2C8 and OATP1B1 inhibitor), rifampicin (OATP1B1 and 1B3 inhibitor) and probenecid (UGT, OAT3 inhibitor) respectively and were not considered clinically relevant. In subjects with normal renal function, co-administration of empagliflozin with probenecid resulted in a 30% decrease in the fraction of empagliflozin excreted in urine without any effect on 24-hour urinary glucose excretion. The relevance of this observation to patients with renal impairment is unknown.

Table 3 Effect of Other Co-Administered Drugs on Pharmacokinetics of Empagliflozin

<u>Co-administered drug</u>	<u>Dose of co-administered drug</u>	<u>Dose of EMPAGLIFLOZIN</u>	<u>Geometric Mean ratio (Ratio with/without co-administered drug) No effect=1.0</u>		<u>Clinical comment</u>
			<u>AUC (90% CI)</u>	<u>C_{max} (90% CI)</u>	
Metformin	1000 mg, bid, 5 days	50 mg, qd, 5 days	0.97 (0.92; 1.02)	1.00 (0.89; 1.14)	No dose adjustment of SYNJARDY required
Glimepiride	1 mg, single dose	50 mg, qd, 6 days	0.95 (0.92; 0.99)	0.96 (0.88; 1.03)	No dose adjustment of SYNJARDY required

<u>Co-administered drug</u>	<u>Dose of co-administered drug</u>	<u>Dose of EMPAGLIFLOZIN</u>	<u>Geometric Mean ratio (Ratio with/without co-administered drug) No effect=1.0</u>		<u>Clinical comment</u>
			<u>AUC (90% CI)</u>	<u>Cmax (90% CI)</u>	
Pioglitazone	45 mg, q.d., 7 days	50 mg, qd, 7 days	1.00 (0.96; 1.05)	0.93 (0.85; 1.03)	No dose adjustment of SYNJARDY required
Warfarin	25 mg, single dose	25 mg, qd, 7 days	1.01 (0.97; 1.05)	1.01 (0.90; 1.13)	No dose adjustment of SYNJARDY required
Sitagliptin	100 mg, qd, 5 days	50 mg, qd, 5 days	1.10 (1.04; 1.17)	1.08 (0.97; 1.19)	No dose adjustment of SYNJARDY required
Linagliptin	5 mg, qd, 7 days	50 mg, qd, 7 days	1.02 (0.97; 1.07)	0.88 (0.79; 0.99)	No dose adjustment of SYNJARDY required
Hydrochlorothiazide	25 mg, qd, 5 days	25 mg, qd, 5 days	1.07 (0.97; 1.18)	1.03 (0.89; 1.19)	No dose adjustment of SYNJARDY required
Torsemide	5 mg, qd, 5 days	25 mg, qd, 5 days	1.08 (1.00; 1.16)	1.08 (0.98; 1.18)	No dose adjustment of SYNJARDY required
Verapamil	120 mg, single dose	25 mg, single dose	1.03 (0.99; 1.07)	0.92 (0.85; 1.00)	No dose adjustment of SYNJARDY required
Ramipril	5 mg, qd, 5 days	25 mg, qd, 5 days	0.97 (0.93; 1.00)	1.04 (0.98; 1.12)	No dose adjustment of SYNJARDY required
Gemfibrozil	600 mg, bid, 5 days	25 mg, single dose	1.59 (1.52; 1.66)	1.15 (1.06; 1.25)	No dose adjustment of SYNJARDY required
Simvastatin	40 mg, single dose	25 mg, single dose	1.02 (0.99; 1.05)	1.09 (0.97; 1.24)	No dose adjustment of SYNJARDY required
Rifampicin	600 mg, single dose	10 mg, single dose	1.35 (1.30; 1.41)	1.75 (1.60; 1.92)	No dose adjustment of SYNJARDY required

<u>Co-administered drug</u>	<u>Dose of co-administered drug</u>	<u>Dose of EMPAGLIFLOZIN</u>	<u>Geometric Mean ratio (Ratio with/without co-administered drug) No effect=1.0</u>		<u>Clinical comment</u>
			<u>AUC (90% CI)</u>	<u>Cmax (90% CI)</u>	
Probenecid	500 mg, bid, 4 days	10 mg, single dose	1.53 (1.46; 1.61)	1.26 (1.14; 1.39)	No dose adjustment of SYNJARDY required

For single dose, AUC is AUC_{0-∞}; for multiple dose, AUC is AUC_{τ,ss}

Effects of empagliflozin on other co-administered drugs

In clinical studies, empagliflozin had no clinically relevant effect on the pharmacokinetics of metformin, glimepiride, pioglitazone, sitagliptin, linagliptin, warfarin (CYP2C9 substrate), digoxin (P-gp substrate), ramipril, simvastatin (CYP3A4, OATP1B1, OATP1B3 substrate), hydrochlorothiazide, torasemide and oral contraceptives ethinyl estradiol and norgestrel (CYP3A4 substrate) when co-administered in healthy volunteers (see [Table 4](#)).

Table 4 Effect of Empagliflozin on Pharmacokinetics of Other Co-Administered Drugs Co-administered drug

	<u>Dose of co-administered drug</u>	<u>Dose of EMPAGLIF LOZIN</u>	<u>Geometric Mean ratio (Ratio with/without co-administered drug) No effect=1.0</u>		<u>Clinical comment</u>
			<u>AUC (90% CI)</u>	<u>Cmax (90% CI)</u>	
Metformin	1000 mg, bid, 5 days	50 mg, qd, 5 days	1.01 (0.96; 1.06)	1.04 (0.97; 1.11)	No dose adjustment required for metformin
Glimepiride	1 mg, single dose	50 mg, qd, 6 days	0.93 (0.86; 1.01)	1.04 (0.89; 1.21)	No dose adjustment required for glimepiride
Pioglitazone	45 mg, q.d., 7 days	50 mg, qd, 7 days	1.58 (1.48; 1.69)	1.88 (1.66; 2.12)	No dose adjustment required for pioglitazone
	45 mg, q.d., 7 days	10 mg, q.d., 9d	0.90 (0.78; 1.04)	0.88 (0.74; 1.04)	
	45 mg, q.d., 7 days	25 mg, q.d., 9d	0.89 (0.73; 1.09)	0.90 (0.67; 1.22)	
	45 mg, q.d., 7 days	50 mg, q.d., 9d	0.91 (0.77; 1.07)	0.90 (0.71; 1.14)	
Warfarin (R-warfarin)	25 mg, single dose	25 mg, qd, 7 days	0.98 (0.95; 1.02)	0.98 (0.91; 1.05)	No dose adjustment required for warfarin
(S-warfarin)			0.96 (0.93; 0.98)	0.99 (0.92; 1.06)	
Sitagliptin	100 mg, qd, 5 days	50 mg, qd, 5 days	1.03 (0.99; 1.07)	1.08 (1.01; 1.17)	No dose adjustment required for sitagliptin
Linagliptin	5 mg, qd, 7 days	50 mg, qd, 7 days	1.03 (0.96; 1.11)	1.01 (0.87; 1.19)	No dose adjustment required for linagliptin
Digoxin	0.5 mg, single dose	25 mg, qd, 8 days	1.06 (0.97; 1.16)	1.14 (0.99; 1.31)	No dose adjustment required for digoxin
Microgynon® tablet	ethinylestradiol, 30 µg, qd, 7 days	25 mg, q.d., 7 days	1.03 (0.98; 1.08)	0.99 (0.93; 1.05)	No dose adjustment required for oral contraceptives
	levonorgestrel 150 µg, qd, 7 days		1.02 (0.99; 1.05)	1.06 (0.99; 1.13)	
Hydrochlorothiazide	25 mg, qd, 5 days	25 mg, qd, 5 days	0.96 (0.89; 1.04)	1.02 (0.89; 1.17)	No dose adjustment required for hydrochlorothiazide

	<u>Dose of co-administered drug</u>	<u>Dose of EMPAGLIF LOZIN</u>	<u>Geometric Mean ratio (Ratio with/without co-administered drug) No effect=1.0</u>		<u>Clinical comment</u>	
			<u>AUC (90% CI)</u>	<u>Cmax (90% CI)</u>		
Torasemide	5 mg, qd, 5 days	25 mg, qd, 5 days	1.01 (0.99; 1.04)		No dose adjustment required for torasemide	
			M1 metabolite	1.04 (1.00; 1.09)		1.03 (0.94; 1.12)
			M3 metabolite	1.03 (0.96; 1.11)		1.02 (0.98; 1.07)
Ramipril	5 mg, qd, 5 days	25 mg, qd, 5 days	1.08 (1.01; 1.16)		No dose adjustment required for ramipril	
			Ramiprilat	0.99 (0.96; 1.01)		0.98 (0.93; 1.04)
Simvastatin	40 mg, single dose	25 mg, single dose	1.01 (0.80; 1.28)		No dose adjustment required for simvastatin	
			Simvastatin acid	1.05 (0.90; 1.22)		0.97 (0.85; 1.11)

For single dose, AUC is AUC_{0-∞}; for multiple dose, AUC is AUC_{τ,ss}

Pharmacodynamic interactions

Diuretics: Empagliflozin may add to the diuretic effect of loop diuretics and may increase the risk of dehydration and hypotension. Caution is recommended when SYNJARDY is co-administered with diuretics; particularly loop diuretics (see [WARNINGS AND PRECAUTIONS](#) and [DOSAGE AND ADMINISTRATION](#)).

Metformin hydrochloride

Glyburide: In a single-dose interaction study in NIDDM subjects, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. Decreases in glyburide AUC and C_{max} were observed, but were highly variable. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamics effects make the clinical significance of this interaction uncertain.

Furosemide: A single-dose study, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by co-administration.

Furosemide increased the metformin plasma and blood C_{max} by 22% and blood AUC by 15%, without any significant change in metformin renal clearance. When administered with metformin, the C_{max} and AUC of furosemide were 31% and 12% smaller, respectively, than when administered alone, and the terminal half-life was decreased by 32%, without any significant change in furosemide renal clearance. No information is available about the interaction of metformin and furosemide when co-administered chronically.

Nifedipine: A single-dose, metformin-nifedipine drug interaction study in healthy volunteers demonstrated that co-administration of nifedipine increased plasma metformin C_{max} and AUC by 20% and 9%, respectively, and increased the amount excreted in the urine. T_{max} and half-life were unaffected. Nifedipine appears to enhance the absorption of metformin. Metformin had minimal effects on nifedipine.

Cationic Drugs: Cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, and vancomycin) that are eliminated by renal tubular secretion theoretically have the potential for interaction with metformin by competing for common renal tubular transport systems. Such an interaction has been observed between metformin and oral cimetidine in normal healthy volunteers in both single and multiple dose, metformin-cimetidine drug interaction studies, with a 60% increase in peak metformin plasma and whole blood concentrations and a 40% increase in plasma and whole blood metformin AUC was observed. There was no change in elimination half-life in the single-dose study. Metformin had no effect on cimetidine pharmacokinetics.

Therefore, careful patient monitoring and dose adjustment of SYNJARDY or the interfering drug is recommended in patients who are taking cationic medications that are excreted via renal tubular secretion.

Other: Other drugs tend to produce hyperglycemia and may lead to a loss of blood sugar control. These include thiazide and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, estrogen plus progestogen, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, isoniazid, and beta-2-agonists.

ACE-inhibitors may decrease the blood glucose levels. When such drugs are administered to patients receiving SYNJARDY, the patient should be closely observed to maintain adequate glycemic control.

Diuretics, especially loop diuretics, may increase the risk of lactic acidosis due to their potential to decrease renal function.

Anticoagulant: Elimination rate of the anticoagulant phenprocoumon has been reported to be increased by 20% when used concurrently with metformin. Therefore, patients receiving phenprocoumon or other antivitamin K anticoagulants should be monitored carefully when both types of drugs used simultaneously. In such cases, an important increase of prothrombin time may occur upon cessation of SYNJARDY therapy, with an increased risk of hemorrhage.

Drug-Food Interactions

Interactions with food have not been established. (see [DOSAGE AND ADMINISTRATION, Dosing Considerations](#)).

Drug-Herb Interactions

Interactions with herbal products have not been established.

Drug-Laboratory Interactions

Empagliflozin

Due to its mechanism of action, patients taking SYNJARDY will test positive for glucose in their urine. Monitoring glycemic control with 1,5-AG assay is not recommended as measurements of 1,5AG are unreliable in assessing glycemic control in patients taking SGLT2 inhibitors. Use alternative methods to monitor glycemic control.

Metformin hydrochloride

Intravascular contrast studies with iodinated materials can lead to acute alteration of renal function and have been associated with lactic acidosis in patients receiving metformin (see [CONTRAINDICATIONS](#) and [WARNINGS AND PRECAUTIONS](#)).

Drug-Lifestyle Interactions

Alcohol

Patients should be cautioned against excessive alcohol intake, either acute or chronic, when taking SYNJARDY, since alcohol intake potentiates the effect of metformin on lactate metabolism (see [CONTRAINDICATIONS](#)). The risk of lactic acidosis is increased in acute alcohol intoxication, particularly in case of fasting or malnutrition or hepatic insufficiency. SYNJARDY is contraindicated in patients with clinical or laboratory evidence of hepatic disease (see [CONTRAINDICATIONS](#)). It is recommended that consumption of alcohol and alcohol-containing medicinal product be avoided.

Effects on Ability to Drive and Use Machines

No studies on the effects on the ability to drive and use machines have been performed. However, patients should be alerted to the elevated risk of adverse reactions related to reduced intravascular volume, such as postural hypotension, and to the risk of hypoglycemia when SYNJARDY is used in combination with insulin or an insulin secretagogue.

DOSAGE AND ADMINISTRATION

Dosing Considerations

Concomitant Use with Insulin or an Insulin Secretagogue (e.g. sulfonylurea): When SYNJARDY is used as add-on therapy with insulin or an insulin secretagogue, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycaemia (see [WARNINGS AND PRECAUTIONS](#)).

Diuretics: SYNJARDY should be used with caution in patients taking diuretics, particularly loop diuretics, due to the increased risk of adverse events due to volume depletion during co-administration.

Recommended Dose and Dosage Adjustment

The recommended dose of SYNJARDY is one tablet twice daily with meals.

The dosage should be individualized on the basis of the patient's current regimen, effectiveness,

and tolerability while not exceeding the maximum recommended daily dose of 25 mg of empagliflozin and 2000 mg of metformin.

SYNJARDY is available in the following dosage strengths:

- 5 mg empagliflozin/500 mg metformin hydrochloride
 - 5 mg empagliflozin/850 mg metformin hydrochloride
 - 5 mg empagliflozin/1000 mg metformin hydrochloride
 - 12.5 mg empagliflozin/500 mg metformin hydrochloride
 - 12.5 mg empagliflozin/850 mg metformin hydrochloride
 - 12.5 mg empagliflozin/1000 mg metformin hydrochloride
-
- In patients on metformin (alone or in combination with a sulfonylurea, pioglitazone, or insulin), switch to SYNJARDY containing empagliflozin 5 mg (10 mg total daily dose) with a similar total daily dose of metformin;
 - Patients switching from separate tablets of empagliflozin (10 mg or 25 mg total daily dose) and metformin to SYNJARDY should receive the same daily dose of empagliflozin and metformin already being taken or the nearest therapeutically appropriate dose of metformin.

Pediatrics (<18 years of age): The safety and efficacy of SYNJARDY in pediatric and adolescent patients have not been established. Therefore, SYNJARDY should not be used in this population.

Geriatrics (≥65 years of age): Due to the potential for decreased renal function in elderly subjects, the dosage of SYNJARDY should be adjusted based on renal function. Regular assessment of renal function is necessary. Initiation of SYNJARDY therapy is not recommended in patients aged ≥85 years as therapeutic experience is limited in this population (see [WARNINGS AND PRECAUTIONS, Geriatrics](#)).

Renal Impairment

SYNJARDY is contraindicated in patients with renal insufficiency (e.g. creatinine clearance <60 mL/min) due to the metformin component (see [CONTRAINDICATIONS](#)).

Hepatic Impairment

SYNJARDY is contraindicated in patients with clinical or laboratory evidence of hepatic disease (see [CONTRAINDICATIONS](#)). Metformin use in patients with impaired hepatic function has been associated with some cases of lactic acidosis (see [WARNINGS AND PRECAUTIONS](#)).

Missed Dose

If a dose is missed, it should be taken as soon as the patient remembers. However, a double dose should not be taken at the same time. In that case, the missed dose should be skipped.

OVERDOSAGE

Symptoms

Empagliflozin

It is reasonable to employ usual supportive measures, e.g., remove unabsorbed material from the gastrointestinal tract, employ clinical monitoring, and institute supportive treatment as dictated by the patient's clinical status. The removal of SYNJARDY by hemodialysis has not been studied.

Metformin hydrochloride

Available information concerning treatment of a massive overdose of metformin hydrochloride is very limited. It would be expected that adverse reactions of a more intense character including epigastric discomfort, nausea and vomiting followed by diarrhea, drowsiness, weakness, dizziness, malaise and headache might be seen. Should those symptoms persist, lactic acidosis should be excluded. Lactic acidosis has been reported in approximately 32% of metformin overdose cases (see [WARNINGS AND PRECAUTIONS](#)).

Overdose of metformin hydrochloride has occurred, including ingestion of amounts greater than 50 grams. Hypoglycemia was reported in approximately 10% of cases.

Metformin is dialyzable with a clearance of up to 170 mL/min under good hemodynamic conditions. Therefore, hemodialysis may be useful for removal of accumulated drug from patients in whom metformin overdose is suspected.

For management of a suspected drug overdose, contact your regional Poison Control Centre.

ACTION AND CLINICAL PHARMACOLOGY

Mechanism of Action

Empagliflozin and metformin hydrochloride

SYNJARDY (empagliflozin and metformin hydrochloride) combines two oral antihyperglycemic agents with complementary mechanisms of action to improve glycemic control in patients with type 2 diabetes: empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, and metformin hydrochloride, a member of the biguanide class.

Empagliflozin

Sodium-glucose co-transporter 2 (SGLT2) is the predominant transporter responsible for reabsorption of glucose from the glomerular filtrate back into the circulation. Empagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, empagliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.

Metformin hydrochloride

Metformin is a biguanide derivative producing an antihyperglycemic effect which can only be observed in man or in the diabetic animal and only when there is insulin secretion. Metformin, at therapeutic doses, does not cause hypoglycemia when used alone in man or in the non-diabetic animal, except when using a near lethal dose. Metformin has no effects on the pancreatic beta cells. The mode of action of metformin is not fully understood. It has been postulated that metformin might potentiate the effect of insulin or that it might enhance the effect of insulin on the peripheral receptor site. This increased sensitivity seems to follow an increase in the number of insulin receptors on cell surface membranes.

Pharmacodynamics

Empagliflozin

Urinary Glucose Excretion: In patients with type 2 diabetes, urinary glucose excretion increased immediately following a dose of SYNJARDY and was maintained at the end of a 4-week treatment period averaging at approximately 64 grams per day with 10 mg empagliflozin and 78 grams per day with 25 mg SYNJARDY once daily.

Urinary Volume: In a 5-day study, mean 24-hour urine volume increase from baseline was 341 mL on Day 1 and 135 mL on Day 5 of empagliflozin 25 mg treatment.

Cardiac Electrophysiology: In a randomized, double-blind, placebo-controlled, active-comparator, crossover study, 30 healthy subjects were administered a single oral dose of empagliflozin 25 mg, empagliflozin 200 mg (8 times the maximum recommended dose), moxifloxacin, and placebo. The empagliflozin 25 mg and 200 mg treatments were not observed to affect the QTc interval, the QRS duration, the PR interval, or heart rate.

Metformin hydrochloride

Few data are available on the relationship between pharmacodynamics and pharmacokinetics, and therefore the effect of metformin on glucose control cannot be predicted from pharmacokinetic data alone. Tissue concentrations of metformin in the dual target sites of the liver and muscle appear to be more informative, and the deep metformin compartment supplying these tissues is critical and related to plasma concentrations. The glucose-lowering action of metformin takes time to be fully expressed and also that activity is not lost immediately on drug withdrawal.

Pharmacokinetics

The bioavailability of metformin and empagliflozin in SYNJARDY tablets was shown to be comparable to that of individual empagliflozin and metformin tablets administered in free combination (see [CLINICAL TRIALS, COMPARATIVE BIOAVAILABILITY STUDIES](#)).

Empagliflozin

Table 5 Summary^a of Empagliflozin Pharmacokinetic Parameters in T2DM Patients

Single dose mean	C _{max,ss} (nmol/L) mean (% CV)	T _{max,ss} (h) (% CV)	AUC _{τ,ss} (nmol.h/L) (% CV)	CL/F _{ss} (ml/min) (% CV)
25 mg qd	687 (18.4)	1.5 (49.9)	4740 (21.2)	203 (21.4)
10 mg qd	259 (24.8)	1.72 (42.5)	1870 (15.9)	202 (15.9)

^a parameters after oral administration of multiple doses of empagliflozin (Day 28)

Absorption

Empagliflozin

After oral administration in patients with T2DM, empagliflozin was rapidly absorbed with peak plasma concentrations occurring at a median T_{max} 1.5 h post-dose. Thereafter, plasma concentrations declined in a biphasic manner with a rapid distribution phase and a relatively slow terminal elimination phase. The steady state mean plasma AUC and C_{max} were 1870 nmol•h/L and 259 nmol/L, respectively, with 10 mg empagliflozin once daily treatment, and 4740 nmol•h/L and 687 nmol/L, respectively, with 25 mg empagliflozin once daily treatment. Population pharmacokinetic analysis results suggested that empagliflozin exposure (AUC) in T2DM patients is approximately 33% higher for doses less than 400 mg compared to healthy volunteers.

Administration of 12.5 mg empagliflozin as a single SYNJARDY 12.5mg/1000mg tablet after intake of a high-fat and high calorie meal resulted in slightly lower exposure; AUC decreased by approximately 9% and C_{max} decreased by approximately 28%, compared to fasted condition. The observed effect of food on empagliflozin pharmacokinetics was not considered clinically relevant and empagliflozin may be administered with or without food. As metformin is recommended to be taken with food, SYNJARDY is recommended to be taken with food.

Metformin hydrochloride

The absolute bioavailability of a metformin hydrochloride 500 mg tablet given under fasting conditions is approximately 50% to 60%. Studies using single oral doses of metformin hydrochloride 500 mg to 1500 mg, and 850 mg to 2550 mg, indicate that there is a lack of dose proportionality with increasing doses, which is due to decreased absorption rather than an alteration in elimination. Food decreases the absorption of metformin, as shown by approximately a 26 % lower mean peak plasma concentration (C_{max}), and a 12 % lower area under the plasma concentration versus time curve (AUC), and a 35-minute prolongation of time to peak plasma concentration (t_{max}) following administration of a 1000mg metformin as single SYNJARDY 12.5mg/1000mg tablet with food, compared to the same tablet strength administered fasting. The clinical relevance of these decreases is unknown. To reduce the gastrointestinal side effects associated with metformin, SYNJARDY is recommended to be taken with food.

Distribution

Empagliflozin

The apparent steady-state volume of distribution was estimated to be 73.8 L, based on a population pharmacokinetic analysis. Following administration of an oral [¹⁴C]-empagliflozin solution to healthy subjects, the red blood cell partitioning was approximately 36.8% and plasma protein binding was 86.2%, mainly to albumin. Protein binding is independent of plasma empagliflozin concentration. There were no relevant changes in protein binding of empagliflozin due to renal or hepatic impairment.

Metformin hydrochloride

Plasma protein binding is negligible. Metformin partitions into erythrocytes. The blood peak is lower than the plasma peak and appears at approximately the same time. The red blood cells most likely represent a secondary compartment of distribution. The mean volume of distribution (V_d) ranged between 63-276 l.

Metabolism

Empagliflozin

No major metabolites of empagliflozin were detected in human plasma and the most abundant metabolites were three glucuronide conjugates (2-O-, 3-O-, and 6-O-glucuronide). Systemic exposure of each metabolite was less than 10% of total drug-related material. *In vitro* studies suggested that the primary route of metabolism of empagliflozin in humans is glucuronidation by the uridine 5'-diphospho-glucuronosyltransferases UGT2B7, UGT1A3, UGT1A8, and UGT1A9.

Metformin hydrochloride

Metformin is not metabolized. Its main sites of concentration are the intestinal mucosa and the salivary glands. The plasma concentration at steady-state ranges about 1 to 2 mcg/mL. Certain drugs may potentiate the effects of metformin (see WARNINGS AND PRECAUTIONS and DRUG INTERACTIONS).

Excretion

Empagliflozin

The apparent terminal elimination half-life of empagliflozin was estimated to be 12.4h and apparent oral clearance was 10.6 L/h based on the population pharmacokinetic analysis. Following administration of an oral [¹⁴C]-empagliflozin solution to healthy subjects, approximately 95.6% of the drug related radioactivity was eliminated in faeces (41.2%) or urine (54.4%). The majority of drug related radioactivity recovered in faeces was unchanged parent drug and approximately half of drug related radioactivity excreted in urine was unchanged parent drug.

Metformin hydrochloride

The drug is excreted in urine at high renal clearance rate of about 450 mL/min. The initial elimination of metformin is rapid with a half-life varying between 1.7 and 3 hours. The terminal elimination phase accounting for about 4 to 5 % of the absorbed dose is slow with a half-life between 9 and 17 hours.

Special Populations and Conditions

Pediatrics (<18 years of age): Studies characterizing the pharmacokinetics of empagliflozin and metformin in paediatric patients have not been performed. Therefore, SYNJARDY should not be used in this patient population.

Geriatrics (≥ 65 years of age):

SYNJARDY

Studies characterizing the pharmacokinetics of empagliflozin and metformin after administration of SYNJARDY in geriatric patients have not been performed. Due to the potential for decreased renal function in elderly subjects, the dosage of SYNJARDY should be adjusted based on renal function. Regular assessment of renal function is necessary SYNJARDY treatment should not be initiated in patients ≥ 85 years of age (see [WARNINGS AND PRECAUTIONS, Geriatrics](#)).

Empagliflozin

Age did not have a clinically meaningful impact on the pharmacokinetics of empagliflozin based on the population pharmacokinetic analysis. The changes in $AUC_{\tau,ss}$ were decreased by 8.06% for patients 35 years of age and increased by 6.43%, and 10.1% for patients 65 and 75 years of age, respectively, compared to patients with an age of 50 years and assuming normal renal function (eGFR 100 mL/min/1.73 m²).

Metformin hydrochloride

Controlled clinical studies of metformin did not include sufficient numbers of elderly patients to determine whether they respond differently from younger patients.

Gender:

Empagliflozin

Gender had no clinically relevant effect on the pharmacokinetics of empagliflozin based on the population pharmacokinetic analysis. $AUC_{\tau,ss}$ in females was 12.8% higher compared to males.

Race:

Empagliflozin

Based on the population pharmacokinetic analysis, AUC of empagliflozin was estimated to be 13.5% higher in Asian patients with a BMI of 25 kg/m² compared to non-Asian patients with a BMI of 25 kg/m². These changes are not considered clinically meaningful.

Hepatic Insufficiency:

SYNJARDY

Use of SYNJARDY is contraindicated in patients with severe hepatic insufficiency and in patients with clinical or laboratory evidence of hepatic disease (see [CONTRAINDICATIONS](#)).

Empagliflozin

In subjects with mild, moderate, and severe hepatic impairment according to the Child-Pugh classification, AUC of empagliflozin increased approximately by 23%, 47%, and 75% and C_{max} by approximately 4%, 23%, and 48%, respectively, compared to subjects with normal hepatic function. Experience in patients with severe hepatic impairment is limited.

Renal Insufficiency:

SYNJARDY is contraindicated in patients with renal insufficiency due to the metformin component (see [CONTRAINDICATIONS](#)).

Body Mass Index:*Empagliflozin*

BMI had no clinically relevant effect on the pharmacokinetics of empagliflozin based on the population pharmacokinetic analysis. The changes in $AUC_{\tau,ss}$ were increased by 7.48% for patients with BMI of 20 kg/m² and decreased by 5.82%, 10.4%, and 17.3% for patients with BMI of 30, 35 and 40 kg/m², respectively, compared to patients with a BMI of 25 kg/m².

Genetic Polymorphism:*Empagliflozin*

The influence of UGT1A9 and other UGT genetic polymorphisms on the pharmacokinetics of empagliflozin have not been evaluated.

STORAGE AND STABILITY

SYNJARDY tablets should be stored at room temperature (15°C – 30°C)

SPECIAL HANDLING INSTRUCTIONS

Store in a safe place and out of the reach and sight of children.

DOSAGE FORMS, COMPOSITION AND PACKAGING

SYNJARDY are film-coated tablets for oral administration.

SYNJARDY 5 mg/500 mg contain 5 mg empagliflozin and 500 mg metformin hydrochloride and are orange yellow, oval, biconvex film-coated tablets; one side debossed with “S5” and company symbol; the other side debossed with “500”.

SYNJARDY 5 mg/850 mg contain 5 mg empagliflozin and 850 mg metformin hydrochloride and are yellowish white, oval, biconvex film-coated tablets; one side debossed with “S5” and company symbol; the other side debossed with “850”.

SYNJARDY 5 mg/1000 mg contain 5 mg empagliflozin and 1000 mg metformin hydrochloride and are brownish yellow, oval, biconvex film-coated tablets; one side debossed with “S5” and company symbol; the other side debossed with “1000”.

SYNJARDY 12.5 mg/500 mg contain 12.5 mg empagliflozin and 500 mg metformin hydrochloride and are pale brownish purple, oval, biconvex film-coated tablets; one side debossed with “S12” and company symbol; the other side debossed with “500”.

SYNJARDY 12.5 mg/850 mg contain 12.5 mg empagliflozin and 850 mg metformin hydrochloride and are pinkish white, oval, biconvex film-coated tablets; one side debossed with “S12” and company symbol; the other side debossed with “850”.

SYNJARDY 12.5 mg/1000 mg contain 12.5 mg empagliflozin and 1000 mg metformin hydrochloride and are dark brownish purple, oval, biconvex film-coated tablets; one side debossed with “S12” and company symbol; the other side debossed with “1000”.



Non-medicinal ingredients: copovidone, hypromellose, iron oxide black and iron oxide red (SYNJARDY 12.5 mg/500 mg, 12.5 mg/850 mg and 12.5 mg/1000 mg), iron oxide yellow (SYNJARDY 5 mg/500 mg, 5 mg/850 mg and 5 mg/1000 mg), macrogol 400, magnesium stearate, maize starch, silica - colloidal anhydrous, talc, titanium dioxide.

SYNJARDY are supplied in blister packages of 6 sheets x 10 tablets (commercial pack) and 1 sheet x 10 tablets (sample).

PART II: SCIENTIFIC INFORMATION

PHARMACEUTICAL INFORMATION

Drug Substance: Empagliflozin plus metformin hydrochloride

Common name: Empagliflozin	Proper name: Metformin Hydrochloride
Chemical name: (1S)-1,5-anhydro-1-(4-chloro-3-{4-[(3S)-tetrahydrofuran-3-yloxy]benzyl}phenyl)-D-glucitol	Chemical name: N, N-dimethyl biguanide hydrochloride
CAS number: 864070-44-0	CAS number: 1115-70-4
Molecular formula and molecular mass: C ₂₃ H ₂₇ ClO ₇ 450.91 g/mol	Molecular formula and molecular mass: C ₄ H ₁₁ N ₅ .HCl 165.63 g/mol
Structural formula: 	Structural formula: 
Empagliflozin is a white to yellowish, not hygroscopic solid powder, very slightly soluble in water (0.28 mg/mL), sparingly soluble in methanol (33.4 mg/mL), slightly soluble in ethanol (8.0 mg/mL), slightly soluble in acetonitrile (2.6 mg/mL), slightly soluble in 50% methanol in water (6.4 mg/mL), soluble in 50% acetonitrile in water (68 mg/mL), and practically insoluble in toluene (<0.001 mg/mL).	Physicochemical properties: Metformin hydrochloride is a white to off-white crystalline compound. Metformin hydrochloride is freely soluble in water and is practically insoluble in acetone, ether, and chloroform.
Solubility data of empagliflozin in aqueous media at room temperature: Water (pH 8.6) 0.28 mg/mL; 0.1N HCl (pH 1.1) 0.30 mg/mL; McIlvaine buffer pH 4.0 (pH 4.1) 0.21 mg/mL; McIlvaine buffer pH 7.4 (pH 7.5) 0.14 mg/mL.	

CLINICAL TRIALS

There have been no clinical studies conducted with SYNJARDY (empagliflozin/metformin hydrochloride) tablets. The bioavailability of metformin and empagliflozin in SYNJARDY tablets was shown to be comparable to that of individual empagliflozin and metformin tablets administered in free combination (see [CLINICAL TRIALS, Comparative Bioavailability Studies](#)).

Empagliflozin

Treatment with empagliflozin in combination with metformin, glimepiride, pioglitazone, or basal and prandial insulin (with metformin) produced clinically relevant and statistically significant improvements in mean change from baseline at Week 24 in HbA1c, fasting plasma glucose (FPG), blood pressure and 2-hour post-prandial glucose (where measured), compared to placebo or control. In the double-blind placebo-controlled extension of these studies, reductions of HbA1c and body weight were sustained up to Week 76. HbA1c reductions were seen across subgroups including gender, age, race, duration of disease, baseline BMI and patients with high baseline HbA1c >10%.

Study demographics and trial design

Table 6 Summary of patient demographics for clinical trials in specific indication

Study No.	Trial design	Dosage, route of administration and duration	Study subjects (n=number) randomised / treated	Mean age years (SD)	Gender (%M/F)
Add-on Combination Therapy with Metformin					
1245.23	Randomised, multicentre, double-blind, placebo-controlled, parallel group	Empagliflozin 10 mg, 25 mg, placebo tablets, Tablets, orally, once daily Run-in: 2 weeks placebo open-label Randomised Treatment: 24 weeks Extension: up to 76 weeks Follow-up: 1 week	Total: 707/706 Empagliflozin: 10 mg: 217/217 25 mg: 214/213 Placebo: 207/207	Empagliflozin: 10 mg: 55.5 (9.9) 25 mg: 55.6 (10.2) Placebo: 56.0 (9.7)	Empagliflozin: 10 mg: 58/42 25 mg: 56/44 Placebo: 56/44
1245.28	Randomised, multicentre, double blind, active-controlled, parallel-group	Empagliflozin 25 mg Glimepiride (Amaryl®):1 to 4 mg Placebo (run-in period) tablets, oral, once daily Run-in: 2 weeks Treatment: 104 weeks Extension: 104 weeks Follow-up: 4 weeks	Total: 1549/1545 (until interim database lock) Empagliflozin: 25 mg: 769/765 Glimepiride 1 to 4 mg: 780/780	Empagliflozin: 25 mg: 56.2 (10.3) Glimepiride: 55.7 (10.4)	Empagliflozin: 25 mg: 56/43 Glimepiride: 54/46
Add-on Combination Therapy with Metformin and a Sulfonylurea					
1245.23+	Randomised, multicentre, double-blind, placebo-controlled, parallel group	Empagliflozin 10 mg, 25 mg, placebo tablets, orally, once daily Run-in: 2 weeks placebo open-label Randomised treatment: 24 weeks Extension: up to 76 weeks	Total: 669/666 Empagliflozin: 10 mg: 226/225 25 mg: 218/216 Placebo: 225/225	Empagliflozin: 10 mg: 57.0 (9.2) 25 mg: 57.4 (9.3) Placebo: 56.9 (9.2)	Empagliflozin: 10 mg: 50/50 25 mg: 53/47 Placebo: 50/50

Study No.	Trial design	Dosage, route of administration and duration	Study subjects (n=number) randomised / treated	Mean age years (SD)	Gender (%M/F)
		Follow-up: 1 week			
Add-on Combination Therapy with Pioglitazone					
1245.19	Randomised, multicentre, double-blind, placebo-controlled parallel group	Empagliflozin 10mg or 25 mg vs placebo Tablets, orally, once daily Run-in: 2 weeks placebo open-label Randomised treatment: 24 weeks Extension: up to 76 weeks Follow-up: 1 week	Total 499/498 patients Empagliflozin 10 mg: 165/165 25 mg: 168/168 Placebo: 166/165	Empagliflozin: 10 mg: 54.7 (9.9) 25 mg: 54.2 (8.9) Placebo: 54.6 (10.5)	Empagliflozin: 10 mg: 50/50 25 mg: 50/50 Placebo: 44/56
Add-on Combination Therapy with MDI of Basal and Prandial Insulin (with or without Metformin)					
1245.49	Randomized, multicentre, double-blind, placebo-controlled, parallel group	E 10mg, 25 mg Placebo tablets, oral, once daily Randomised treatment: 52 weeks Week 1-18 & 41-52 - stable insulin dose Week 19-40, treat-to-target insulin dose	Total: 566/563 Empagliflozin: 10 mg: 187/186 25 mg: 190/189 Placebo: 189/188	Empagliflozin: 10 mg: 56.7 (8.7) 25 mg: 58.0 (9.4) Placebo: 55.3 (10.1)	Empagliflozin: 10 mg: 52/48 25 mg: 44/56 Placebo: 40/60

Study results

Add-on Therapy with Metformin (Study 1245.23)

A double-blind, placebo-controlled study of 24 weeks duration was conducted to evaluate the efficacy and safety of empagliflozin in patients not sufficiently treated with metformin. As shown in [Table 7](#), statistically significant ($p < 0.0001$) reductions in HbA1c, FPG and body weight relative to placebo were observed with empagliflozin 10 mg and 25 mg at Week 24.

Table 7 Results of a 24-Week (LOCF) Placebo-Controlled Study of EMPAGLIFLOZIN as Add-on Combination with Metformin

Efficacy Parameter	Placebo	EMPAGLIFLOZIN 10 mg	EMPAGLIFLOZIN 25 mg
N	207	217	213
HbA1c (%)			
Baseline (mean)	7.90	7.94	7.86
Change from baseline ¹	-0.13	-0.70	-0.77
Difference from placebo ¹ (97.5% CI)		-0.57* (-0.72, -0.42)	-0.64* (-0.79, -0.48)
N	184	199	191
Patients² (%) achieving HbA1c <7%	16.4	40.6	40.8
N	207	216	213
FPG (mmol/L)			
Baseline (mean)	8.66	8.58	8.29
Change from baseline ¹	0.35	-1.11	-1.24

Efficacy Parameter	Placebo	EMPAGLIFLOZIN 10 mg	EMPAGLIFLOZIN 25 mg
Difference from placebo ¹ (95% CI)		-1.47 (-1.74, -1.20)	-1.59 (-1.86, -1.32)
N	207	217	213
Body Weight (kg)			
Baseline (mean)	79.73	81.59	82.21
Change from baseline ¹	-0.45	-2.08	-2.46
Difference from placebo ¹ (97.5% CI)		-1.63* (-2.17, -1.08)	-2.01* (-2.56, -1.46)

¹ mean adjusted for baseline value

² The HbA1c responder analyses were performed on FAS with a noncompleters considered failure (NCF) imputation approach by determining the percentage of patients that fulfil responder criteria.

*p-value <0.0001

The first measurement of HbA1c after initiation of the treatment period occurred at week 6 and resulted in significant reductions in HbA1c with empagliflozin 10 mg and 25 mg vs placebo (-0.46% and -0.51% respectively; p<0.0001) which were sustained over time.

Add-on Therapy with Metformin - Active-Controlled Study versus Glimperide (Study 1245.28)

In a study comparing the efficacy and safety of empagliflozin 25 mg versus glimepiride (4 mg) in patients with inadequate glycemic control on metformin alone, as shown in [Table 8](#), empagliflozin daily resulted in a statistically significant (p<0.0001) reduction in HbA1c, FPG and body weight at Week 104. Systolic blood pressure (SBP, mmHg) change from baseline was -3.1, and 2.5 for empagliflozin 25 mg, and glimepiride respectively.

Treatment with empagliflozin resulted in statistically significantly lower proportion of patients with hypoglycaemic events compared to glimepiride (2.5% for empagliflozin 25 mg, 24.2% for glimepiride, p<0.0001).

Table 8 Results at 104-Week (LOCF) in an Active-Controlled Study Comparing EMPAGLIFLOZIN to Glimepiride as Add-on to Metformin

Efficacy Parameter	EMPAGLIFLOZIN 25 mg	Glimepiride
N	765	780
HbA1c (%)		
Baseline (mean)	7.92	7.92
Change from baseline ¹	-0.66	-0.55
Difference from glimepiride ¹ (97.5% CI)	-0.11*(-0.20, -0.01)	
N	690	715
Patients² (%) achieving HbA1c <7%	37.5	32.6
N	764	779
FPG (mmol/L)		
Baseline (mean)	8.33	8.32
Change from baseline ¹	-0.85	-0.17
Difference from glimepiride ¹ (95% CI)	-0.69 (-0.86, -0.52)	
N	765	780

Efficacy Parameter	EMPAGLIFLOZIN 25 mg	Glimepiride
Body Weight (kg)		
Baseline (mean)	82.52	83.03
Change from baseline ¹	-3.12	1.34
Difference from glimepiride ¹ (97.5% CI)	-4.46** (-4.87, -4.05)	

¹ mean adjusted for baseline value

² The HbA1c responder analyses were performed on FAS with a noncompleters considered failure (NCF) imputation approach by determining the percentage of patients that fulfil responder criteria.

* p<0.0001 for non-inferiority, p<0.0153 for superiority

** p-value <0.0001

The first measurement of HbA1c after initiation of the treatment period occurred at week 4 and resulted in reductions in HbA1c with empagliflozin 25 mg and glimepiride vs baseline (-0.41% and -0.43% respectively) which were sustained over time.

Add-on Therapy with Metformin and Sulfonylurea (Study 1245.23+)

A double-blind, placebo-controlled study of 24 weeks duration was conducted to evaluate the efficacy and safety of empagliflozin in patients not sufficiently treated with a combination of metformin and a sulphonylurea. As shown in [Table 9](#), treatment with empagliflozin resulted in statistically significant (p<0.0001) reductions in HbA1c and body weight, and clinically meaningful reductions in FPG compared to placebo at Week 24.

Table 9 Results of a 24-Week (LOCF) Placebo-Controlled Study of EMPAGLIFLOZIN as Add-on Therapy to Metformin with a Sulfonylurea

Efficacy Parameter	Placebo	EMPAGLIFLOZIN 10 mg	EMPAGLIFLOZIN 25 mg
N	225	225	216
HbA1c (%)			
Baseline (mean)	8.15	8.07	8.10
Change from baseline ¹	-0.17	-0.82	-0.77
Difference from placebo ¹ (97.5% CI)		-0.64* (-0.79, -0.49)	-0.59* (-0.74, -0.44)
N	216	209	202
Patients² (%) achieving HbA1c <7%	11.1	31.1	34.3
N	224	225	215
FPG (mmol/L)			
Baseline (mean)	8.42	8.38	8.68
Change from baseline ¹	0.31	-1.29	-1.29
Difference from placebo ¹ (95% CI)		-1.60 (-1.90, -1.30)	-1.60 (-1.90, -1.29)
N	225	225	216
Body Weight (kg)			
Baseline (mean)	76.23	77.08	77.50
Change from baseline ¹	-0.39	-2.16	-2.39

Efficacy Parameter	Placebo	EMPAGLIFLOZIN 10 mg	EMPAGLIFLOZIN 25 mg
Difference from placebo ¹ (97.5% CI)		-1.76* (-2.25, -1.28)	-1.99* (-2.48, -1.50)

¹ mean adjusted for baseline value

² The HbA1c responder analyses were performed on FAS with a noncompleters considered failure (NCF) imputation approach by determining the percentage of patients that fulfil responder criteria.

*p-value <0.0001

The first measurement of HbA1c after initiation of the treatment period occurred at week 6 and resulted in significant reductions in HbA1c with empagliflozin 10 mg and 25 mg vs placebo (-0.58% and -0.6% respectively; p<0.0001) which were sustained over time.

Add-on Therapy with MDI of Basal and Prandial Insulin (with Metformin) (Study 1245.49)

The efficacy and safety of empagliflozin as add on to multiple daily injections of basal and prandial insulin with metformin were evaluated at Week 18 and Week 52 in a randomized, double-blind, placebo-controlled study of empagliflozin 10 mg and 25 mg. From Week 1 to Week 18, patients were to maintain a stable insulin dose. From Week 19 to 40, treat-to-target insulin dose adjustments were to be made as needed in order to achieve glucose treat-to-target values (pre-prandial 5.5 mmol/L and post-prandial 7.8 mmol/L). From Week 41 to Week 52, patients were to maintain a stable insulin dose, and adjustments were to be made for safety reasons only. Insulin mix, regular and/or analogue mix, have not been studied.

The primary endpoint was the change from baseline in HbA1c after 18 weeks of treatment, analyzed on the full analysis set (FAS-18). As shown in [Table 10](#), statistically significant reduction in HbA1c relative to placebo was observed with empagliflozin 10 mg and 25 mg at Week 18.

Table 10 Results of 18-Week Placebo-Controlled Study- FAS (LOCF-18) of EMPAGLIFLOZIN in Combination with Insulin with Metformin

Efficacy Parameter	Placebo	EMPAGLIFLOZIN 10 mg	EMPAGLIFLOZIN 25 mg
All patients, N	188	186	189
Insulin+metformin, N (%)	135 (71.8)	128 (68.8)	137 (72.5)
HbA1c (%)			
Baseline ² (mean) (SE)	8.29 (0.06)	8.42 (0.06)	8.29 (0.06)
Change from baseline ¹ mean (SE) (at Week 18)	-0.58 (0.06)	-0.99 (0.06)	-1.03 (0.06)
Difference from placebo ¹ 97.5% confidence interval	--	-0.41 (-0.61, -0.21)	-0.45 (-0.65, -0.25)
p-value	--	<0.0001	<0.0001

During the first 18 weeks of treatment, the background insulin dose was not to be changed.

SE= standard error

¹ adjusted mean for baseline HbA1c, eGFR and geographical region

² Model included baseline HbA1c (p<0.0001) as a linear covariate, baseline eGFR (MDRD) (p=0.7812), treatment (p<0.0001), baseline background medication (p=0.0541), and treatment by baseline background medication interaction (p=0.3254) as fixed effects.

Add-on Therapy with Pioglitazone (with or without Metformin, Study 1245.19)

The efficacy and safety of empagliflozin were evaluated in a double-blind, placebo-controlled study of 24 weeks duration in patients not sufficiently treated with a combination of metformin

and pioglitazone or pioglitazone alone. As shown in [Table 11](#), empagliflozin in combination with pioglitazone (mean dose ≥ 30 mg) with or without metformin resulted in statistically significant ($p < 0.0001$) reductions in HbA1c, fasting plasma glucose, and body weight compared to placebo at Week 24.

Table 11 Results of a 24-Week (LOCF) Placebo-Controlled Study of EMPAGLIFLOZIN as Add-on to Pioglitazone

Efficacy Parameter	Placebo	EMPAGLIFLOZIN 10 mg	EMPAGLIFLOZIN 25 mg
N	165	165	168
HbA1c (%)			
Baseline (mean)	8.16	8.07	8.06
Change from baseline ¹	-0.11	-0.59	-0.72
Difference from placebo ¹ (97.5% CI)		-0.48* (-0.69, -0.27)	-0.61* (-0.82, -0.40)
N	155	151	160
Patients² (%) achieving HbA1c <7%	9.7	27.9	31.5
N	165	163	168
FPG (mmol/L)			
Baseline (mean)	8.43	8.44	8.43
Change from baseline ¹	0.37	-0.94	-1.23
Difference from placebo ¹ (97.5% CI)		-1.32 (-1.72, -0.91)	-1.61 (-2.01, -1.21)
N	165	165	168
Body Weight (kg)			
Baseline (mean)	78.1	77.97	78.93
Change from baseline ¹	0.34	-1.62	-1.47
Difference from placebo ¹ (97.5% CI)		-1.95* (-2.64, -1.27)	-1.81* (-2.49, -1.13)

¹ mean adjusted for baseline value

² The HbA1c responder analyses were performed on FAS with a noncompleters considered failure (NCF) imputation approach by determining the percentage of patients that fulfil responder criteria.

*p-value <0.0001

The first measurement of HbA1c after initiation of the treatment period occurred at week 6 and resulted in significant reductions in HbA1c with empagliflozin 10 mg and 25 mg vs placebo (-0.4% and -0.51% respectively; $p < 0.0001$) which were sustained over time.

Empagliflozin twice daily versus once daily as add on to metformin therapy (1276.10)

The efficacy and safety of empagliflozin twice daily versus once daily (daily dose of 10 mg and 25 mg) as add-on therapy in patients with insufficient glycaemic control on metformin monotherapy was evaluated in a double blind placebo-controlled study of 16 weeks duration. The total number of randomized patients per stratum was: 219 (empagliflozin 12.5 mg bid), 218 (empagliflozin 25 mg qd), 219 (empagliflozin 5 mg bid), 220 (empagliflozin 10 mg qd) and 107 (placebo).

In all treatment groups, empagliflozin provided significant HbA1c (SE), [95% CI] reductions compared with placebo at 16 weeks: -0.61% (0.09), [(-0.79, -0.44)] for empagliflozin 12.5 mg bid, -0.50% (0.09), [(-0.68, -0.32)] for empagliflozin 25 mg once daily, -0.44% (0.09), [(-0.62, -0.27)] for empagliflozin 5 mg twice daily, and -0.42% (0.09), [(-0.60, -0.25)] for empagliflozin 10 mg once daily (p<0.0001 for each comparisons).

Comparative Bioavailability Studies

The bioavailability of metformin and empagliflozin in SYNJARDY tablets was shown to be comparable to that of individual empagliflozin and metformin tablets administered in free combination.

The results of bioequivalence studies in healthy subjects demonstrated that SYNJARDY (empagliflozin/metformin hydrochloride) 5 mg/500 mg, 5 mg/850 mg, 5 mg/1000 mg, 12.5 mg/500 mg, 12.5 mg/850 mg, and 12.5 mg/1000 mg combination tablets are bioequivalent to co-administration of corresponding doses of empagliflozin and metformin as individual tablets.

Administration of 12.5 mg empagliflozin/1000 mg metformin under fed conditions resulted in a 9% decrease in AUC and a 28% decrease in C_{max} for empagliflozin, when compared to fasted conditions. For metformin, AUC decreased by 12% and C_{max} decreased by 26% compared to fasting conditions. The observed effect of food on empagliflozin and metformin is not considered to be clinically relevant.

However, as metformin is recommended to be given with meals, SYNJARDY is also proposed to be given with food.

SUMMARY TABLE OF THE COMPARATIVE BIOAVAILABILITY DATA

Empagliflozin (1 x 12.5 mg) From measured data uncorrected for potency Geometric Mean Arithmetic Mean (CV %)				
Parameter	Test* (FDC fed)	Reference† (Single tablets fasted)	% Ratio of Geometric Means	90% Confidence Interval#
AUC _T ‡ (nmol·h/L)	2610 2640 (15.1)	2760 2800 (18.6)	94.39	89.22 – 99.87
AUC ₁ (nmol·h/L)	2680 2710 (15.0)	2820 2860 (18.5)	94.94	89.85 – 100.33
C _{max} (nmol/L)	253 259 (20.3)	400 405 (15.8)	64.30	55.97 – 73.87
T _{max} § (h)	3.00 (1.00 – 8.00)	1.75 (1.00-2.50)		
T _{1/2} Ⓒ (h)	16.7 (43.0)	16.0 (61.3)		

* Identity of the test product: Treatment C (fed): Empagliflozin 12.5 mg/metformin hydrochloride 1000 mg FDC tablet, oral [B101002752]

† Identity of the reference product, including the manufacturer, and origin (country of purchase): Treatment B (fasted): Individual tablets of empagliflozin 2.5 mg and 10 mg tablet, oral, [2.5 mg: B091004302, 10 mg: 909475A] and metformin hydrochloride 1000 mg tablet, oral [X1750]

‡ For drugs with a half-life greater than 24 hours AUC_T should be replaced with AUC₀₋₇₂

§ Expressed as the median (range)

° Expressed as the arithmetic mean (CV%)

SUMMARY TABLE OF THE COMPARATIVE BIOAVAILABILITY DATA

Metformin (1 x 1000 mg) From measured data uncorrected for potency Geometric Mean Arithmetic Mean (CV %)				
Parameter	Test* (FDC fed)	Reference† (Single tablets fasted)	% Ratio of Geometric Means	90% Confidence Interval#
AUC _T ‡ (ng·h/L)	9330 9550 (19.7)	9470 9720 (22.3)	96.96	87.23 – 107.78
AUC ₁ (ng·h/L)	10100 10200 (15.6)	9910 10100 (21.2)	100.67	91.70 – 110.51
C _{max} (ng/mL)	1120 1180 (25.5)	1480 1530 (23.4)	75.13	63.68 – 88.64
T _{max} § (h)	3.00 (1.50 – 8.00)	2.50 (1.50 – 4.00)		
T _½ ° (h)	30.5 (89.0)	17.8 (76.9)		

* Identity of the test product: Treatment C (fed): Empagliflozin 12.5 mg/metformin hydrochloride 1000 mg FDC tablet, oral [B101002752]

† Identity of the reference product, including the manufacturer, and origin (country of purchase): Treatment B (fasted): Individual tablets of empagliflozin 2.5 mg and 10 mg tablet, oral, [2.5 mg: B091004302, 10 mg: 909475A] and metformin hydrochloride 1000 mg tablet, oral [X1750]

‡ For drugs with a half-life greater than 24 hours AUC_T should be replaced with AUC₀₋₇₂

§ Expressed as the median (range)

° Expressed as the arithmetic mean (CV%)

Comparative Bioavailability of Metformin

The comparative bioavailability of metformin was assessed in a randomized, two-way cross-over study in healthy adult male and female subjects. Subjects were administered single doses of 500 mg metformin as SYNJARDY fixed dose combination (FDC) tablets (1 x 12.5 mg/500 mg empagliflozin/metformin) or as individual Glucophage® (metformin hydrochloride) (sanofi-aventis Canada Inc.) tablets (1 x 500 mg) in combination with a single empagliflozin 12.5 mg dose (1 x 2.5 mg + 1 x 10 mg), in the fed state.

SUMMARY TABLE OF THE COMPARATIVE BIOAVAILABILITY DATA

Metformin (1 x 500 mg) From measured data Adjusted Geometric Mean Arithmetic Mean (CV %)				
Parameter	Test* (FDC tablet)	Reference† (Single tablets)	% Ratio of Geometric Means	90% Confidence Interval
AUC _T (ng·h/mL)	6256 6380 (19.9)	6347 6490 (19.9)	98.6	94.7 – 102.6
AUC ₁ (ng·h/mL)	6410 6540 (20.2)	6522 6660 (20.2)	98.3	94.5 – 102.2
C _{max} (ng/mL)	746.3 762 (20.5)	754.3 773 (22.0)	98.9	95.9 – 102.1
T _{max} § (h)	4.00 (1.00 – 8.00)	4.00 (1.00 – 6.00)		
T _½ ε (h)	20.0 (80.4)	24.1 (80.2)		

*Empagliflozin/metformin FDC 12.5 mg empagliflozin/500 mg metformin tablet (Boehringer Ingelheim, Germany)

†Empagliflozin 10 mg and 2.5 mg tablets (Boehringer Ingelheim, Germany) administered with Glucophage® (metformin hydrochloride) 500 mg tablets (sanofi-aventis Canada, Inc., Canada)

§ Expressed as the median (range)

ε Expressed as the arithmetic mean (CV%)

Comparative Bioavailability of Empagliflozin

The comparative bioavailability of empagliflozin was assessed in three randomized, four-way cross-over studies conducted in healthy adult male and female subjects. Subjects were administered single doses of 5 mg or 12.5 mg empagliflozin as SYNJARDY fixed dose combination tablets or as individual empagliflozin and metformin tablets administered together, under fed conditions.

Bioavailability of empagliflozin in SYNJARDY fixed dose combination tablets (1 x 5 mg/500 mg or 1 x 12.5 mg/500 mg empagliflozin/metformin) compared with the free combination of individual empagliflozin (1 x 5 mg or 1 x 2.5 mg + 1 x 10 mg) tablets administered with 1 x 500 mg metformin:

SUMMARY TABLES OF THE COMPARATIVE BIOAVAILABILITY DATA

Empagliflozin (1 x 5 mg)				
From measured data				
Geometric Mean				
Arithmetic Mean (CV %)				
Parameter	Test* (FDC tablet)	Reference [†] (Single tablets)	% Ratio of Geometric Means	90% Confidence Interval [#]
AUC _T (nmol·h/L)	1080 1090 (15.9)	1040 1060 (18.3)	102.77	99.15 – 106.52
AUC _I (nmol·h/L)	1110 1120 (15.9)	1070 1090 (18.3)	102.79	99.08 – 106.63
C _{max} (nmol/L)	109 112 (23.4)	106 108 (23.3)	102.96	97.92 – 108.26
T _{max} [§] (h)	2.50 (1.00 – 6.00)	2.75 (1.00 – 5.00)		
T _½ ^ε (h)	10.2 (23.8)	9.76 (28.6)		

*Empagliflozin/metformin FDC 5 mg empagliflozin/500 mg metformin tablet (Boehringer Ingelheim, Germany)

[†]Empagliflozin 5 mg tablets (Boehringer Ingelheim, Germany) administered with Glucophage® (metformin hydrochloride) 500 mg tablet (Merck Pharma GmbH, Germany).

[§] Expressed as the median (range)

^ε Expressed as the arithmetic mean (CV%)

SUMMARY TABLES OF THE COMPARATIVE BIOAVAILABILITY DATA

Empagliflozin (1 x 12.5 mg)				
From measured data				
Geometric Mean				
Arithmetic Mean (CV %)				
Parameter	Test* (FDC tablet)	Reference [†] (Single tablets)	% Ratio of Geometric Means	90% Confidence Interval [#]
AUC _T (nmol·h/L)	2740 2780 (16.1)	2830 2870 (17.5)	98.00	93.53 – 102.69
AUC _I (nmol·h/L)	2780 2820 (16.0)	2870 2910 (17.5)	97.92	93.53 – 102.52
C _{max} (nmol/L)	294 302 (24.4)	282 292 (26.7)	104.61	99.88 – 109.56
T _{max} [§] (h)	2.50 (1.00 – 8.00)	2.52 (0.667 – 5.00)		
T _½ ^ε (h)	12.3 (30.4)	11.7 (34.1)		

*Empagliflozin/metformin FDC 12.5 mg empagliflozin/500 mg metformin tablet (Boehringer Ingelheim, Germany)

[†]Empagliflozin 2.5 mg + 10 mg tablets (Boehringer Ingelheim, Germany) administered with Glucophage® (metformin hydrochloride) 500 mg tablet (Merck Pharma GmbH, Germany).

[§] Expressed as the median (range)

^ε Expressed as the arithmetic mean (CV%)

Bioavailability of empagliflozin in SYNJARDY fixed dose combination tablets (1 x 5 mg/850 mg or 1 x 12.5 mg/850 mg empagliflozin/metformin) compared with the free combination of individual empagliflozin (1 x 5 mg or 1 x 2.5 mg + 1 x 10 mg) tablets administered with 1 x 850 mg metformin:

SUMMARY TABLES OF THE COMPARATIVE BIOAVAILABILITY DATA

Empagliflozin (1 x 5 mg)				
From measured data				
Geometric Mean				
Arithmetic Mean (CV %)				
Parameter	Test* (FDC tablet)	Reference† (Single tablets)	% Ratio of Geometric Means	90% Confidence Interval#
AUC _T (nmol·h/L)	963 995 (25.0)	946 971 (23.2)	100.31	97.41 – 103.30
AUC _I (nmol·h/L)	986 1020 (24.8)	968 994 (22.9)	100.30	97.40 – 103.29
C _{max} (nmol/L)	103 106 (21.9)	101 104 (25.5)	100.97	95.94 – 106.27
T _{max} [§] (h)	2.50 (0.667 – 6.03)	2.50 (0.667 – 6.00)		
T _½ ^ε (h)	8.6 (17.1)	8.3 (21.2)		

*Empagliflozin/metformin FDC 5 mg empagliflozin/850 mg metformin tablet (Boehringer Ingelheim, Germany)

†Empagliflozin 5 mg tablets (Boehringer Ingelheim, Germany) administered with Glucophage® (metformin hydrochloride) 850 mg tablet (Merck Pharma GmbH, Germany).

§ Expressed as the median (range)

ε Expressed as the arithmetic mean (CV%)

SUMMARY TABLES OF THE COMPARATIVE BIOAVAILABILITY DATA

Empagliflozin (1 x 12.5 mg)				
From measured data				
Geometric Mean				
Arithmetic Mean (CV %)				
Parameter	Test* (FDC tablet)	Reference† (Single tablets)	% Ratio of Geometric Means	90% Confidence Interval#
AUC _T (nmol·h/L)	2520 2590 (24.6)	2490 2590 (30.1)	101.20	96.89 – 105.71
AUC _I (nmol·h/L)	2560 2640 (24.9)	2530 2630 (30.6)	101.31	96.89 – 105.93
C _{max} (nmol/L)	266 272 (20.5)	258 263 (21.3)	102.70	98.75 – 106.81
T _{max} [§] (h)	3.00 (0.983 – 8.03)	3.00 (0.667 – 6.05)		
T _½ ^ε (h)	9.7 (28.7)	9.4 (29.7)		

*Empagliflozin/metformin FDC 12.5 mg empagliflozin/850 mg metformin tablet (Boehringer Ingelheim, Germany)

†Empagliflozin 2.5 mg + 10 mg tablets (Boehringer Ingelheim, Germany) administered with Glucophage® (metformin hydrochloride) 850 mg tablet (Merck Pharma GmbH, Germany).

§ Expressed as the median (range)

ε Expressed as the arithmetic mean (CV%)

Bioavailability of empagliflozin in SYNJARDY fixed dose combination tablets (1 x 5 mg/1000 mg or 1 x 12.5 mg/1000 mg empagliflozin/metformin) compared with the free combination of individual empagliflozin (1 x 5 mg or 1 x 2.5 mg + 1 x 10 mg) tablets administered with 1 x 1000 mg metformin:

SUMMARY TABLES OF THE COMPARATIVE BIOAVAILABILITY DATA

Empagliflozin (1 x 5 mg)				
From measured data				
Geometric Mean				
Arithmetic Mean (CV %)				
Parameter	Test* (FDC tablet)	Reference† (Single tablets)	% Ratio of Geometric Means	90% Confidence Interval
AUC _T ‡ (nmol·h/L)	962 974 (16.6)	903 917 (19.0)	105.98	102.73 – 109.33
AUC _I (nmol·h/L)	988 1000 (16.5)	927 941 (18.8)	106.00	102.73 – 109.39
C _{max} (nmol/L)	108 110 (17.9)	103 104 (14.4)	104.54	99.15 – 110.22
T _{max} § (h)	2.50 (0.667 – 5.00)	2.50 (0.667 – 5.00)		
T _½ € (h)	10.8 (37.1)	10.2 (30.6)		

*Empagliflozin/metformin FDC 5 mg empagliflozin/1000 mg metformin tablet (Boehringer Ingelheim, Germany)

†Empagliflozin 5 mg tablets (Boehringer Ingelheim, Germany) administered with Glucophage® (metformin hydrochloride) 1000 mg tablets (Merck Pharma GmbH, Germany).

§ Expressed as the median (range)

€ Expressed as the arithmetic mean (CV%)

SUMMARY TABLES OF THE COMPARATIVE BIOAVAILABILITY DATA

Empagliflozin (1 x 12.5 mg)				
From measured data				
Geometric Mean				
Arithmetic Mean (CV %)				
Parameter	Test* (FDC tablet)	Reference† (Single tablets)	% Ratio of Geometric Means	90% Confidence Interval
AUC _T ‡ (nmol·h/L)	2530 2580 (19.1)	2510 2560 (21.0)	98.82	94.78 – 103.04
AUC _I (nmol·h/L)	2580 2630 (19.3)	2570 2620 (21.4)	98.88	94.88 – 103.06
C _{max} (nmol/L)	276 284 (26.4)	258 268 (29.6)	106.52	95.86 – 118.35
T _{max} § (h)	2.00 (0.667 – 6.00)	2.75 (0.667 – 8.00)		
T _½ € (h)	10.6 (31.5)	11.5 (31.6)		

*Empagliflozin/metformin FDC 12.5 mg empagliflozin/1000 mg metformin tablet (Boehringer Ingelheim, Germany)

†Empagliflozin 2.5 mg + 10 mg tablets (Boehringer Ingelheim, Germany) administered with Glucophage® (metformin hydrochloride) 1000 mg tablets (Merck Pharma GmbH, Germany).

§ Expressed as the median (range)

€ Expressed as the arithmetic mean (CV%)

DETAILED PHARMACOLOGY

Empagliflozin and metformin hydrochloride

Treatment of male Zucker Diabetic Fatty rats (ZDF, fa/fa) for 1 month with empagliflozin (3 mg/kg/day) in combination with metformin (300 mg/kg/day) was associated increased plasma insulin, increased insulin AUC, decreased plasma glucose, decreased glucose AUC and decreased whole blood HbA1c that was greater than either empagliflozin alone (3 mg/kg/day) or metformin alone (300 mg/kg/day).

Empagliflozin

Empagliflozin demonstrated good *in vitro* potency towards inhibition of human (IC₅₀ of 1.3 nM) and rat (IC₅₀ of 1.7 nM) renal SGLT2 transporters. The three major human metabolites of empagliflozin, all glucuronides, exhibited very weak activity toward the SGLT2 transporter *in vitro*, with IC₅₀ values ranging from 860 – 1435 nM. Oral doses of empagliflozin increased urinary glucose excretion in diabetic rodents and normoglycemic dogs. This triggered the lowering of blood glucose in diabetic rodents after single oral dosing, as well as after chronic treatment.

Metformin hydrochloride

The mechanism of the antihyperglycemic effect of metformin is not completely understood and probably several actions are involved. The following mechanisms of action have been suggested: 1) increased insulin receptor binding; 2) decreased intestinal glucose absorption; 3) increased cellular glucose uptake; 4) decreased hepatic gluconeogenesis; 5) stimulation of anaerobic glycolysis; and 6) potentiation of insulin action at the receptor or post-receptor level.

TOXICOLOGY

Single-dose toxicity

Empagliflozin

Empagliflozin demonstrated low acute toxicity. The single lethal oral dose of empagliflozin was greater than 2000 mg/kg in mice and rats.

Repeat-dose toxicity

Empagliflozin and metformin hydrochloride

The repeat-dose toxicity of empagliflozin in combination with metformin was evaluated in a pivotal 90-day rat study at 200:0, 0:400, 50:100, 100:200 and 200:400 mg/kg/day empagliflozin:metformin. While treatment with empagliflozin in combination with metformin was not associated with new toxicities, exacerbation of several parameters (including hypochloremia; a marker for acid-base disturbances) was observed at 100:200 and 200:400 mg/kg/day empagliflozin:metformin when compared with empagliflozin alone and metformin alone. The no-observed-adverse-effect-level (NOAEL) was considered to be 50:100 mg/kg/day empagliflozin:metformin (approximately 4-times the maximum daily dose of empagliflozin of 25 mg and 2-times the maximum daily dose of metformin of 2000 mg, both based on AUC) based on the observation of hypochloremia at 100:200 and 200:400 mg/kg/day empagliflozin:metformin.

Empagliflozin

Repeat-dose oral toxicity studies were conducted in mice, rats and monkeys for up to 13, 26, and 52 weeks, respectively. Signs of toxicity were generally observed at exposures greater than or equal to 10 times the human exposure (AUC) at the maximum recommended dose of 25 mg. Most toxicity was consistent with secondary pharmacology related to urinary glucose loss and included decreased body weight and body fat, increased food consumption, diarrhea, dehydration, decreased serum glucose and increases in other serum parameters reflective of increased protein metabolism, gluconeogenesis and electrolyte imbalances, urinary changes such as polyuria and glycosuria. Increases in liver weight, elevated hepatic enzyme activities (e.g., AST and ALT) and hepatocellular vacuolation were observed in mice, rats and dogs. These changes in the liver may be related to gluconeogenesis and/or mobilization of lipid for energy production. The main target organ of empagliflozin toxicity was the kidney. Microscopic changes in the kidney were observed across species and included tubular karyomegaly, single cell necrosis, cystic hyperplasia and hypertrophy (mouse), renal mineralization and cortical tubular vacuolation (rat), and tubular nephropathy and interstitial nephritis (dog).

In a 2-year study in mice, mortality associated with urinary tract lesions was dose-dependently increased for males given empagliflozin at oral doses of ≥ 100 mg/kg/day (≥ 4 times the clinical dose of 25 mg based on AUC comparisons).

Metformin hydrochloride

The repeat-dose toxicity of metformin was evaluated in a two-week rat study at 100, 200 and 1000 mg/kg/day and a 90-day rat study at 200:0, 0:400, 50:100, 100:200 and 200:400 mg/kg/day empagliflozin:metformin. Metformin was well tolerated up to 400 mg/kg/day which approximates 5-times the maximum daily dose of metformin of 2000 mg (based on AUC), with no remarkable toxicological findings at this dose level. At 1000 mg/kg/day, myocardial hypertrophy, vacuolation of the adrenal medulla, pituitary hyperplasia, depletion of zymogen granules in the pancreas, and reduced size of cortical areas in the thymus was observed.

Genotoxicity

Empagliflozin

Empagliflozin was not genotoxic in the Ames bacterial reverse mutation assay, the L5178/tk+/- mouse lymphoma assay, or the *in vivo* rat micronucleus test.

Metformin hydrochloride

Metformin was not genotoxic in the Ames bacterial reverse mutation assay, mouse lymphoma assay, chromosome aberration test (human lymphocytes), and the *in vivo* mouse micronucleus assay.

Carcinogenicity

Empagliflozin

The carcinogenic potential of empagliflozin was evaluated in 2-year studies in mice and rats. Empagliflozin did not increase the incidence of tumors in female rats up to the highest dose of 700 mg/kg/day (up to 72 times the clinical dose of 25 mg based on AUC comparisons). In male rats, treatment-related benign vascular proliferative lesions (hemangiomas) of the mesenteric lymph node were observed at 700 mg/kg/day (approximately 42 times the clinical dose of 25 mg

based on AUC comparisons), but not at 300 mg/kg/day which corresponds to approximately 26 times the clinical exposure from 25 mg dose. These tumors are common in rats and the incidence (18%) was within literature historical control (0-26%). No vascular lesions were seen in the mouse and dog. Empagliflozin did not increase the incidence of tumors in female mice at doses up to 1000 mg/kg/day (up to, approximately 62 times the clinical dose of 25 mg based on AUC comparisons). Renal tumors were observed in male mice at 1000 mg/kg/day (approximately 45 times the clinical dose of 25 mg based on AUC comparisons), but not at 300 mg/kg/day which corresponds to approximately 11 times the clinical exposure from a 25 mg dose. The mode of action for these tumors may be dependent on the natural predisposition of the male mouse to renal pathology which is exacerbated by a male mouse kidney-specific cytotoxic oxidative metabolite. Therefore the renal tumors found in mice may not be relevant to patients given clinical doses of empagliflozin.

Metformin hydrochloride

Long-term carcinogenicity studies have been performed in rats (dosing duration of 104 weeks) and mice (dosing duration of 91 weeks) at doses up to and including 900 mg/kg/day and 1500 mg/kg/day, respectively. These doses are both approximately 4 times the maximum recommended human daily dose of 2000 mg based on body surface area comparisons. No evidence of carcinogenicity with metformin was found in either male or female mice. Similarly, there was no tumorigenic potential observed with metformin in male rats. An increased incidence of benign stromal uterine polyps in female rats treated with 900 mg/kg/day.

Reproductive Toxicity

Empagliflozin and metformin hydrochloride

The effect of empagliflozin in combination with metformin on embryo-fetal development was evaluated in Wistar Han rats at 30:60, 100:200, 300:600, 300:0 and 0:600 mg/kg empagliflozin:metformin administered from gestation day (GD) 7 to 16. Fetal skeletal malformations were observed at 300:600 mg/kg empagliflozin:metformin and consisted of flat and thickened rib, cleft cervical vertebral body, and sternbrae branched, fused or misshapen and were considered metformin related. This was based on an embryo-fetal development study in Wistar Han rats with metformin at 200, 500 and 1000 mg/kg administered from GD 7 to 16. Fetal external and skeletal malformations were observed at 500 and 1000 mg/day (systemic exposure equal to 11 and 23 times the MRHD of 2000 mg/day, respectively) and consisted of unilateral anophthalmia (1 fetus at 1000 mg/kg), polydactylia (1 fetus at 1000 mg/kg), flat and thickened rib (500 and 1000 mg/kg), rib z-shaped (1000 mg/kg). The NOAEL was considered to be 200 mg/kg (systemic exposure equal to 4 times the MRHD of 2000 mg/day). The NOAEL was considered to be 100:200 mg/kg empagliflozin:metformin, which approximates 14-times the maximum daily dose of empagliflozin of 25 mg and 4-times the maximum daily dose of metformin of 2000 mg (based on AUC).

Empagliflozin

In a study of fertility and early embryonic development in rats, empagliflozin had no effects on mating and fertility in males or females or early embryonic development up to the highest dose of 700 mg/kg/day (approximately 50 times the clinical dose of 25 mg based on AUC comparisons).

Empagliflozin administered during the period of organogenesis was not teratogenic at doses up to 300 mg/kg/day in the rat or rabbit, which corresponds to approximately 48 times or 128 times the clinical dose of 25 mg based on AUC comparisons, respectively. Doses of empagliflozin causing maternal toxicity in the rat also caused the malformation of bent limb bones at exposures approximately 155 times the clinical exposure from a 25 mg dose. Maternally toxic doses in the rabbit also caused increased embryofetal loss at doses approximately 139 times the clinical dose of 25 mg based on AUC comparisons.

In a pre- and postnatal toxicity study in rats, empagliflozin was administered from gestation day 6 through to lactation day 20 (weaning) at 10, 30 and 100 mg/kg/day, and pups were indirectly exposed in utero and throughout lactation. There was no evidence of maternal toxicity up to the high dose of 100 mg/kg/day; however, a reduction in F1 pup body weight gains, mainly during lactation, was observed at doses of ≥ 30 mg/kg/day (≥ 4 times the clinical dose of 25 mg based on AUC comparisons). The F1 male pups also had learning and memory deficits at 100 mg/kg (approximately 16 times the clinical dose of 25 mg based on AUC comparisons) on postnatal day (PND) 22, but not on PND 62. These neurobehavioral effects were likely to be secondary to the retarded growth rates of the F1 male pups. The NOAEL for F1 neonatal toxicity was 10 mg/kg/day (approximately 1.4 times the clinical dose of 25 mg based on AUC comparisons).

In a juvenile toxicity study, empagliflozin was administered directly to young rats from postnatal day 21 until postnatal day 90 at oral doses of 1, 10, 30 and 100 mg/kg/day. Increases in kidney weights were observed in males at ≥ 10 mg/kg/day (≥ 0.7 times the clinical dose of 25 mg based on AUC comparisons) and in females at ≥ 30 mg/kg/day (≥ 4 times the clinical dose of 25 mg based on AUC comparisons). Minimal to mild renal tubular and pelvic dilation was seen at 100 mg/kg/day, which approximates 11-times the clinical dose of 25 mg based on AUC comparisons. These findings were absent after a 13-week, drug-free recovery period.

Metformin hydrochloride

Metformin was not teratogenic in Sprague Dawley rats and rabbits at doses up to 600 mg/kg/day at about 2 times the MRHD based on body surface area comparisons. Fertility of male or female Sprague Dawley rats was unaffected by metformin when administered at doses as high as 600 mg/kg/day, which is approximately 2 times the MRHD based on body surface area comparisons.

REFERENCES

1. Macha S, Sennewald R, Rose P, Schoene K, Pinnetti S, Woerle HJ, Broedl UC. Lack of clinically relevant drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and verapamil, ramipril, or digoxin in healthy volunteers. *Clin Ther.* 2013;35(3):226-35.
2. Macha S, Mattheus M, Pinnetti S, Woerle HJ, Broedl UC. Effect of Empagliflozin on the Steady-State Pharmacokinetics of Ethinylestradiol and Levonorgestrel in Healthy Female Volunteers. *Clin Drug Investig.* 2013 Mar 20. [Epub ahead of print] doi: 10.1007/s40261-013-0068-y
3. Macha S, Dieterich S, Mattheus M, Seman LJ, Broedl UC, Woerle HJ. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT2) inhibitor, and metformin following co-administration in healthy volunteers. *Int J Clin Pharmacol Ther.* 2013;51(2):132-40.
4. Macha S, Rose P, Mattheus M, Pinnetti S, Woerle HJ. Lack of drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and warfarin in healthy volunteers. *Diabetes Obes Metab.* 2013;15(4):316-23
5. Brand T, Macha S, Mattheus M, Pinnetti S, Woerle HJ. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers. *Adv Ther.* 2012;29(10):889-99.
6. Grempler R, Thomas L, Eckhardt M, Himmelsbach F, Sauer A, Sharp DE, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. *Diabetes Obesity and Metabolism, Diabetes Obes Metab* 2012;14(1):83-90. (P11-13842)
7. Ridderstråle M, Svaerd R, Zeller C, Kim G, Woerle Hand, Broedl U. Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycaemic control. *Cardiovasc Diabetol* 2013; 12: 129. P13-11052
8. Roden M, Weng J, Eilbracht J, Delafont B, Kim G, Woerle H, Broedl U. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Diabetes Endocrinol* 2013; 1(3): 208–19. P13-11200
9. Häring HU, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Woerle H, Broedl U. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week randomized, double-blind, placebo-controlled trial. *Diabetes Care* 2013; 36(11): 3396–404. P13-08968

10. Kovacs C, Seshiah V, Swallow R, Jones R, Rattunde H, Woerle H, Broedl U. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. *Diabetes Obes Metab* 2014;16(2):147–58. P13-09179
11. Barnett AH, Mithal A, Manassie J, Jones R, Rattunde H, Woerle H, Broedl U. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. *Lancet Diabetes Endocrinol* 2014; [Epub ahead of print]; doi:10.1016/S2213-8587(13)70208-0. P14-01211
12. Rosenstock J, Jelaska A, Wang F, Kim G, Broedl U, Woerle H. Empagliflozin as add-on to basal insulin for 78 weeks improves glycaemic control with weight loss in insulin-treated type 2 diabetes (T2DM). *Diabetologia* 2013; 56 (suppl 1): S372 [931]
13. Mithal A, Barnett AH, Manassie J, Jones R, Rattunde H, Woerle H, Broedl U. Empagliflozin in patients with type 2 diabetes mellitus (T2DM) and stage 3A, 3B and 4 chronic kidney disease (CKD). *Diabetologia* 2013; 56 (suppl 1): S382 [952]
14. Tikkanen I, Narko K, Zeller C, Green A, Salsali A, Broedl U, Woerle H. Empagliflozin improves blood pressure in patients with type 2 diabetes (T2DM) and hypertension. *Diabetologia* 2013; 56 (suppl 1): S377 [942]
15. Sanofi-Aventis Canada Inc. Product Monograph-GLUCOPHAGE® (Metformin Hydrochloride Tablets) 500 mg, 850 mg and 1000 mg tablets. Date of Revision: September 10, 2015 Submission Control No.: 156892]

**READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE
PATIENT MEDICATION INFORMATION**

PrSynjardy™

empagliflozin and metformin hydrochloride tablets

Read this carefully before you start taking SYNJARDY and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about SYNJARDY.

Serious Warnings and Precautions

- SYNJARDY can cause a rare but serious side effect called **lactic acidosis**. This is a buildup of lactic acid in the blood. There is an increased risk after excessive alcohol consumption. This is more common if you are also fasting, malnourished, or have liver disease. Lactic acidosis is a medical emergency and must be treated in a hospital. It can cause coma or death. Therefore, you should not drink alcohol if you take SYNJARDY.
- Diabetic ketoacidosis (DKA) is a serious and life-threatening condition that requires urgent hospitalization. DKA has been reported in patients with type 2 diabetes mellitus (T2DM), with normal or high blood sugar levels, who are treated with SYNJARDY and other sodium-glucose co-transporter 2 (SGLT2) inhibitors. Some cases of DKA have led to death.
- Seek medical attention right away **and stop taking SYNJARDY immediately** if you have any of the following symptoms (even if your blood sugar levels are normal): difficulty breathing, nausea, vomiting, stomach pain, loss of appetite, confusion, feeling very thirsty, feeling unusually tired, a sweet smell to the breath, a sweet or metallic taste in the mouth or a different odour to urine or sweat.
- SYNJARDY should not be used in patients with type 1 diabetes.
- SYNJARDY should not be used to treat DKA or if you have a history of DKA.

What is SYNJARDY used for?

SYNJARDY is used along with diet and exercise to improve control of blood sugar in adults with type 2 diabetes.

SYNJARDY can be used:

- in patients who are not controlled on metformin alone or on a combination of metformin with:
 - a sulfonylurea;
 - pioglitazone;
 - insulin.

- in patients who are currently treated with combinations of separate tablets of metformin and empagliflozin (JARDIANCE), or a combination of metformin and empagliflozin (JARDIANCE) with:
 - a sulfonyleurea;
 - pioglitazone;
 - insulin.

How does SYNJARDY work?

SYNJARDY contains two drugs.

Empagliflozin: removes excess glucose from the body and passes it through the urine.

Metformin: helps to lower the amount of sugar made by your liver.

What are the ingredients in SYNJARDY?

Medicinal ingredients: empagliflozin and metformin hydrochloride.

Non-medicinal ingredients: copovidone, hypromellose, iron oxide black and iron oxide red (SYNJARDY 12.5 mg/500 mg, 12.5 mg/850 mg and 12.5 mg/1000 mg), iron oxide yellow (SYNJARDY 5 mg/500 mg, 5 mg/850 mg and 5 mg/1000 mg), macrogol 400, magnesium stearate, maize starch, silica - colloidal anhydrous, talc, titanium dioxide.

SYNJARDY comes in tablets in the following strengths:

Empagliflozin and metformin hydrochloride:

- 5 mg/500 mg, 5 mg/850 mg, 5 mg/1000 mg;
- 12.5 mg/500 mg, 12.5 mg/850 mg, 12.5 mg/1000 mg.

Do not use SYNJARDY if you:

- have type 1 diabetes (your body does not produce insulin);
- have a complication of diabetes with increased ketones in the blood or urine, known as **diabetic ketoacidosis (DKA)** or a history of DKA;
- have a build-up of acid in your body. This is known as metabolic acidosis;
- have a history of lactic acidosis;
- are taking an insulin mix (regular or analogue);
- are on dialysis;
- have kidney problems;
- have liver problems;
- have severe infections or are experiencing trauma;
- are prior to surgery or during the recovery time;
- are prior to or just after certain x-ray tests with iodinated dyes or contrast agents that are injected into your body;
- have abrupt failure of blood circulation. This is known as cardiovascular collapse;
- have heart and lungs that do not function properly. This is known as cardiorespiratory insufficiency;
- drink alcohol very often, or drink a lot of alcohol in a short time. This is known as binge drinking;
- are breast-feeding;
- are pregnant, or planning to become pregnant;
- are under 18 years of age;

- are allergic to any of the ingredients in SYNJARDY.

To help avoid side effects and ensure proper use, talk to your healthcare professional before you start taking SYNJARDY. Talk about any health conditions or problems you may have, including if you:

- have or have had any kidney problems;
- have or have had any cases of liver disease;
- have congestive heart failure, especially if it needs treatment with medicines;
- have heart problems, or low blood pressure;
- are older than 65 years old. And, if you are 85 years old or older you should not start taking SYNJARDY;
- have an increased chance of developing **diabetic ketoacidosis (DKA)**, including if you:
 - are dehydrated or suffer from excessive vomiting, diarrhea, or sweating;
 - are on a very low carbohydrate diet;
 - drink alcohol very often, or drink a lot of alcohol over a short period of time (binge drinking);
 - have/have had problems with your pancreas, including pancreatitis or surgery on your pancreas;
 - are hospitalized for major surgery, serious infection or serious medical illnesses;
 - have a history of DKA.

Other warnings you should know about

You have a higher chance of getting lactic acidosis if you:

- have any of the first three conditions from the bulleted list just above;
- drink alcohol very often, or drink a lot of alcohol over a short period of time (binge drinking);
- are dehydrated or suffer from excessive vomiting, diarrhea, or sweating;
- have certain x-ray tests with iodinated dyes or contrast agents that are injected into your body;
- have surgery;
- have a heart attack, severe infection, or stroke;
- are 80 years of age or older and have not been assessed for kidney function.

SYNJARDY may cause changes in the amount of cholesterol or fats in your blood.

SYNJARDY may cause abnormal kidney function. Your doctor will do blood tests to monitor how well your kidneys are working while you are taking SYNJARDY.

SYNJARDY increases the chance of getting a yeast infection of the penis or vagina. This is more likely in people who have had yeast infections in the past.

Driving and using machines: SYNJARDY may cause dizziness or lightheadedness. Do not drive or use machines until you know how the medicine affects you.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

The following may interact with SYNJARDY:

- diuretics, known as water pills, such as furosemide. They are used to remove excess water from the body;
- medicines used to lower blood sugar levels, such as glyburide, gliclazide or glimepiride (sulfonylureas) or insulin. Taking SYNJARDY with any of these medicines can increase the risk of having low blood sugar (hypoglycemia);
- medicines used to lower high blood pressure; such as angiotensin converting enzyme (ACE) inhibitors. ACE inhibitors may lower blood glucose;
- antibiotics used to treat tuberculosis, such as rifampin or isoniazid;
- blood thinners, known as anticoagulants;
- cationic drugs. For example, amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, and vancomycin;
- drugs that can increase the blood sugar include:
 - corticosteroids, an anti-inflammatory medicine such as prednisone. They are used to treat inflammation in diseases like asthma or arthritis;
 - tranquilizing drugs, such as phenothiazines. They are known as antipsychotics;
 - thyroid products. They are used to treat problems with the thyroid gland;
 - birth control pills;
 - drugs used to control seizures, such as phenytoin;
 - niacin, also known as vitamin B₃ or nicotinic acid;
 - drugs used to treat angina. They are known as calcium channel blockers. An example is nifedipine;
 - bronchodilators, such as beta-2-agonists. They are used to treat asthma.

Prior to Surgery: Stop SYNJARDY 2 days before any surgery that limits what you eat and drink. You can re-start SYNJARDY once you can eat and drink and your doctor decides that your kidneys are working.

Prior to Certain X-ray Tests with Iodinated Dyes or Contrast Agents that are Injected Into Your Body: Stop SYNJARDY at the time of the test or just before. Re-start SYNJARDY 48 hours after the test and your doctor decides that your kidneys are working.

How to take SYNJARDY:

Your doctor will tell you how much SYNJARDY to take. The amount of SYNJARDY that you take depends on your condition and the doses you currently take of metformin and/or individual tablets of empagliflozin and metformin. Take only the dose that has been prescribed to you. If you are not sure what your dose is, ask your doctor.

Diet and exercise can help your body use its blood sugar better. It is important to stay on the diet and exercise program recommended by your doctor while taking SYNJARDY.

Taking SYNJARDY with meals may lower your chance of having an upset stomach.

Do not stop taking SYNJARDY without first consulting your doctor. Your blood sugar levels may increase when you stop taking SYNJARDY.

Recommended Adult Dose: One tablet two times a day with food. Swallow the tablet whole with water.

Overdose:

If you think you have taken too much SYNJARDY, contact your healthcare professional, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.

Missed Dose:

- If you forget to take a dose of SYNJARDY, take it as soon as you remember. However, if it is nearly time for the next dose, skip the missed dose.
- Do not take a double dose to make up for a forgotten dose. Never take two doses of SYNJARDY at the same time.

What are possible side effects from using SYNJARDY?

These are not all the possible side effects you may feel when taking SYNJARDY. If you experience any side effects not listed here, contact your healthcare professional. Please also see the **Serious Warnings and Precautions** box.

Side effects may include:

- constipation;
- dehydration;
- unusual thirst;
- dry mouth;
- joint pain;
- muscle spasms.

Your doctor will tell you how to treat low blood sugar levels and what to do if you get any of the signs described below. If you have symptoms of low blood sugar, eat glucose tablets, a high sugar snack or drink fruit juice. Measure your blood sugar, if possible and rest.

An urge to pass urine or more frequent urination may be due to the way SYNJARDY works, but can also be a sign of urinary tract infection. If you note an increase in such symptoms, you should contact your doctor.

Diabetic Ketoacidosis (DKA) is a serious medical condition with normal or high blood glucose levels. Get immediate medical help if you have any of the symptoms described in the table below under DKA, even if your blood glucose levels are normal.

SYNJARDY will cause your urine to test positive for sugar (glucose). This is expected when you take SYNJARDY. You should use a different way to monitor your diabetes.

SYNJARDY can cause abnormal blood test results. Your doctor will decide when to perform tests and will interpret the results. They may check your blood fat levels, the amount of red blood

cells in your blood, and check your eyes, heart, liver and kidney function.

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
VERY COMMON			
Low blood sugar (hypoglycemia): shaking; sweating; feeling very anxious or confused; fast heart beat; feeling excessive hunger; headache.		✓	
Nausea	✓		
Vomiting	✓		
Diarrhea	✓		
Stomach ache	✓		
Loss of appetite	✓		
COMMON			
Urinary tract infection: burning sensation when passing urine; urine that appears cloudy; pain in the pelvis; or mid-back pain when kidneys are infected.		✓	
Volume depletion (loss of needed fluids from the body, dehydration, especially in patients older than 75 years of age): dry or sticky mouth; headache; dizziness; urinating less often than normal.		✓	
Genital yeast infections, (reported more frequently in female patients): itching; burning; soreness; irritation; pain during intercourse and/or urination; vaginal discharge.		✓	
Increased urination: passing more urine than usual or needing to pass urine more often.	✓		
Itching	✓		
Changes in taste	✓		
Allergic skin reactions: rash, redness of the skin, hives, swelling of your lips, face, throat or tongue that may cause difficulty in breathing or swallowing.			✓

UNCOMMON			
Low Blood Pressure: dizziness; fainting; lightheadedness. May occur when you go from lying to sitting to standing up.		✓	
Dysuria: Straining or pain when emptying the bladder.		✓	
Kidney problems: any change in the amount, frequency or colour (pale or dark) of urine.		✓	
Acute kidney infection: painful, urgent or frequent urination, lower back (flank) pain, fever or chills, cloudy or foul smelling urine, blood in your urine.			✓
Severe infection that spreads from urinary tract throughout body (sepsis): fever or low body temperature, chills, rapid breathing, rapid heartbeat, pain with urination, difficulty urinating, frequent urination.			✓
RARE			
Diabetic Ketoacidosis (DKA): difficulty breathing; feeling very thirsty; vomiting; stomach pain; nausea; loss of appetite; confusion; unusual tiredness, a sweet smell to the breath, a sweet or metallic taste in the mouth, or a different odour to urine or sweat.			✓
VERY RARE			
Lactic Acidosis: feel very weak or tired; have unusual muscle pain; have trouble breathing or fast breathing; have unusual fatigue, drowsiness or sleepiness or sleep longer than usual; have sudden stomach or intestinal problems with nausea and vomiting or diarrhea; feel cold, especially in your arms and legs; feel dizzy or lightheaded; have a slow or irregular heartbeat; a medical condition suddenly changes; you develop or experience a worsening			✓

of heart problems and in particular heart failure.			
Vitamin B₁₂ deficiency: (decreased vitamin B ₁₂ levels in the blood): fatigue; shortness of breath; tingling or numbness of the fingers or toes; difficulty walking properly; irritability; confusion; tender calves.		✓	
Hepatitis: Yellowing of the skin or eyes; dark urine; abdominal pain; nausea; vomiting; loss of appetite.		✓	

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, talk to your healthcare professional.

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (<https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada.html>) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:

Keep out of reach and sight of children. Store at room temperature (15-30°C). Do not use this medicine after the expiry date which is stated on the blister and the carton. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to dispose medicines you no longer use. These measures will help protect the environment.

If you want more information about SYNJARDY:

- Talk to your healthcare professional.
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada Website (<https://www.canada.ca/en/health-canada.html>), the manufacturer’s website (<http://www.boehringer-ingelheim.ca>), or by calling the manufacturer, Boehringer Ingelheim (Canada) Ltd., at: 1-800-263-5103, extension 84633.

This leaflet was prepared by Boehringer Ingelheim (Canada) Ltd. The information in this leaflet is current up to the time of the last revision date shown below, but more current information may be available from the manufacturer.

Last revised: September 18, 2017

BI logo
Boehringer Ingelheim (Canada) Ltd.
Burlington, ON, Canada L7L 5H4

Co-promoted with:
Lilly logo
Eli Lilly Canada Inc.
Toronto, ON, Canada M1N 2E8